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Abstract 
Kidney cancer is a common adult malignancy in the United States. Clear cell renal cell carcinoma 
(ccRCC), the predominant subtype of kidney cancer, is characterized by widespread metabolic changes. 
Urea metabolism is one such altered pathway in ccRCC. This is reflected in the lowered mRNA and 
protein levels of enzymes ASS1, ASL, and ARG2 in tumor samples when compared to the normal kidney. 
These three enzymes play a critical role in nitrogen metabolism, and alterations in their levels and 
functions have profound effects on cellular growth. ARG2 is located in the mitochondria of renal cells, and 
its loss promotes growth by conserving pools of an essential biosynthetic co-factor, pyridoxal -5- 
phosphate, and preventing a toxic build-up of polyamines. However, ASS1 and ASL are cytosolic in their 
subcellular location, and ostensibly act independently of ARG2 to suppress growth in ccRCC by depleting 
cellular aspartate pools and altering pyrimidine synthesis. Overall, our results uncover a delicate 
metabolic balance in ccRCC cells that is disrupted by the re-expression of urea cycle enzymes. Taken 
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ABSTRACT 
TUMOR SUPPRESSIVE ROLE OF UREA CYCLE ENZYMES IN RENAL CARCINOMA 
Sanika Vinayak Khare 
M. Celeste Simon
Kidney cancer is a common adult malignancy in the United States. Clear cell 
renal cell carcinoma (ccRCC), the predominant subtype of kidney cancer, is 
characterized by widespread metabolic changes. Urea metabolism is one such altered 
pathway in ccRCC. This is reflected in the lowered mRNA and protein levels of enzymes 
ASS1, ASL, and ARG2 in tumor samples when compared to the normal kidney. These 
three enzymes play a critical role in nitrogen metabolism, and alterations in their levels 
and functions have profound effects on cellular growth. ARG2 is located in the 
mitochondria of renal cells, and its loss promotes growth by conserving pools of an 
essential biosynthetic co-factor, pyridoxal -5- phosphate, and preventing a toxic build-up 
of polyamines. However, ASS1 and ASL are cytosolic in their subcellular location, and 
ostensibly act independently of ARG2 to suppress growth in ccRCC by depleting cellular 
aspartate pools and altering pyrimidine synthesis. Overall, our results uncover a delicate 
metabolic balance in ccRCC cells that is disrupted by the re-expression of urea cycle 
enzymes. Taken together, our data seek to establish a metabolic tumor suppressive role 
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CHAPTER 1: INTRODUCTION 
 
Introduction to inborn errors of metabolism  
Inborn errors of metabolism (IEM) are a diverse, yet not uncommon, group of 
disorders that occur due to mutations or deficiencies in a single enzyme of a metabolic 
pathway. In the early 1900s A.E. Garrod, a British physician, described four such 
inherited disorders of metabolism. Since then this number has grown to over 750 IEMs. 
IEMs affect about 1/1000 children and are passed on in an autosomal recessive manner 
(with a few exceptions). Although a vast majority of IEMS manifest shortly after birth, 
some symptoms develop over an individual’s lifetime, and can make diagnosis 
challenging. However, early intervention, and genetic testing for newborns has made 
some IEMs more manageable (Kiess et al., 2020).  
Metabolic disorders in neonates can be classified in a number of ways. 
Commonly, they are divided are into three categories: disorders involving biochemical 
pathways, disorders involving energy metabolism, and disorders involving complex 
molecules (Saudubray et al., 2018).  
The first category of IEMs is vast and affects a variety of pathways. It includes 
both acute and progressive accumulation of normal and/or toxic metabolites arising from 
a block in the affected metabolic pathway. These can result from mutations in amino 
acid catabolism, urea cycle defects, carbohydrate defects and porphyrias. The table 
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Table 1: Examples of Disorders Involving Biochemical Pathways 
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The second category of IEMs involves defects in glucose transport and 
metabolism, fatty acid oxidation, and mitochondrial respiration. Whereas disturbances 
caused by faulty glucose and fatty acid catabolism can be partially managed by 
providing exogenous supplements, mitochondrial defects are usually untreatable with a 
dismal prognostic outlook. These include mutations in the electron transport chain, 
pyruvate metabolism, tricarboxylic acid cycle, and pentose phosphate pathway.  
The final category of metabolic disorders relates to the synthesis, catabolism and 
maintenance of complex molecules. These disorders are usually progressive in nature 
and do not respond to dietary interventions. They include inborn errors in lysosomal 
storage, nucleotide synthesis, cholesterol and bile synthesis, and vesicular trafficking 
among others. Diagnosis and management can be difficult and treatment options are 
limited (El-Hattab, 2015, Fukao and Nakamura, 2018). 
Urea cycle in development and disease 
Urea cycle disorders are one of the most common forms of IEMs (Haberle et al., 
2012). They belong to the first category of defects and are caused by malfunctions in 
urea cycle components.  
Protein homeostasis in the body is a fine balance between protein uptake, 
synthesis, and breakdown. Dietary proteins are constantly broken down into amino acids 
which are then repurposed for endogenous protein synthesis. This protein breakdown 
generates ammonia. The most common enzymatic reactions that result in ammonia 
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Bacterial Deaminase (large 
intestine) 
Amino acids 
Urease (large intestine) Urea 
 
Table 2: Sources of Urea in vivo 
Ammonia produced by protein catabolism in other tissues is transported to the 
liver as glutamine. This glutamine is converted to glutamate to release ammonia, via 
transamination. Ammonia is extremely toxic and is converted to the relatively non-toxic 
urea by the urea cycle. Although some steps of the cycle are also carried out in the 
kidney and other tissues of the body, the liver is the main site of ureagenesis. The non-
hepatic urea cycle components are thought to be involved in arginine biosynthesis and 




Figure 1: The Hepatic Urea Cycle 
Figure 1 represents the urea cycle as it is present in the liver. In the first step of 
the cycle, the enzyme Carbamoylphosphate synthase 1 (CPS1) catalyzes the 
conversion of ammonia and bicarbonate into carbamoyl phosphate. This reaction occurs 
in the mitochondrial matrix, and N-acetylglutamate (NAG), magnesium and ATP act as 
co-activators. The carbamoyl phosphate thus produced is combined with ornithine to 
generate citrulline in a reaction catalyzed by the enzyme ornithine transcarbamylase 
(OTC).  The transporter SLC25a15 or ORNT1 transports citrulline to the cytoplasm while 
citrin (aspartate-glutamate shuttle) carries aspartate from the mitochondria. Enzyme 
argininosuccinate synthase 1 (ASS1) condenses citrulline and aspartate to form 
argininosuccinate, which is then cleaved by argininosuccinate lyase (ASL) to form 
arginine and fumarate. Arginine is finally acted on by arginase 1 (ARG1) to form urea 
and regenerate ornithine. The produced urea is subsequently excreted from the body.  
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Urea cycle disorders (UCDs) are caused by mutations or insufficiencies in any of these 
components (Erez, 2012, Nagamani, et al., 2011, Erez, et al., 2011). All disorders 
barring OTC insufficiency are passed on in an autosomal recessive manner. OTC 
insufficiency is X-linked. The table below summarizes the various UCDs (Summar et al., 
2013) 
Gene Frequency Manifestation 
CPS1 (2q25) 1/975,000 
Most severe form. Neonatal hyperammonemia 





Same as CPS1 deficiency but can be completely 





Hemizygous male neonates have 
hyperammonemia. Late-onset disease is episodic 
in nature. 
ASS1 (9q34) 1/57000 
Wide range of symptoms – asymptomatic to 





Symptoms are caused by arginine deficiency 
and/or argininosuccinate build up. Neonatal 
hyperammonemia, cognitive defects, 




ARG1 (6q23) 1/300,000 
Developmental delay, intellectual defects, 
hepatomegaly, seizures. Elevated arginine in 





Increased amino acids in the blood, along with 
galactose. Intrahepatic cholestasis. 
ORNT1 
(13q1) 
100 cases till 
date 
Causes hyperornithinemia, hyperammonemia, 
homocitrullinuria. Coagulation defects, vomiting 
and lethargy are observed. Physical and cognitive 
growth is negatively impacted. 
 
Table 3: List of Urea Cycle Disorders 
 
IEM and Cancer 
Metabolic rewiring has been long regarded as a hallmark of malignant 
transformation. Studying transformed metabolism is not limited to a single event, rather it 
is akin to observing changes in a complex and wide network of genes, enzymes, 
metabolites and microenvironments. The study of inborn errors of metabolism offers a 
unique perspective into understanding cancer metabolism. It allows us to observe 
network-wide effects of a single enzyme change – from genetics to protein function to 




Tumorigenesis involves excessive growth and cellular transformation, both of 
which are accompanied by underlying metabolic changes. There are several 
mechanisms by which primary metabolic disruptions in IEMs can cause cancer. 
Hepatocellular carcinoma (HCC) is one of the most common forms of cancers 
associated with IEMs. Inactivation of certain metabolic enzymes in the liver leads to 
chronic and toxic accumulation of intermediates which in turn causes tissue damage, 
fibrosis and eventually cancer. IEMs associated with this mechanism include tyrosinemia 
type I, hemochromatosis, Wilson’s disease, and mitochondrial DNA depletion 
syndromes. In a similar manner, renal cell carcinoma (RCC) is associated with Fabry 
disease while bone and hematological malignancies with Gaucher disease (Nelson et 
al., 1995, Lithner et al., 1984, Savas et al., 2006, Cassiman et al., 2007).  
Similarly, loss of function mutations in metabolic enzymes fumarate hydratase 
(FH) and succinate dehydrogenase (SDH, A-D, F) lead to accumulation of their 
substrates – fumarate and succinate. These tricarboxylic acid (TCA) cycle intermediates 
are implicated in tumorigenesis in some forms of kidney and neuroendocrine tumors. 
On the other hand, altered metabolism may give rise to “altered” metabolites. 
These “altered” metabolites can promote malignancy without inciting chronic tissue 
damage and are often termed “oncometabolites”. The most studied oncometabolite is D-
2-hydroxyglutarate (D-2HG), produced by a gain-of-function mutations in the TCA cycle 
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2 (Yang et al., 2013, Intlekofer et 
al., 2018).  Levels of fumarate, succinate and D-2HG affect the activity of a-ketoglutarate 
dependent dioxygenases and they in turn modulate the redox balance, hypoxic signaling 
and epigenetic landscapes, and lead to malignant transformation. However, children with 
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biallelic loss of these enzymes exhibit physical and intellectual growth defects and often 
die early because of which they do not get cancers. 
Mitochondrial IEMs and Cancer 
Mitochondrial disorders form another important link between malignancy and 
IEMs. Mitochondria are critical for a number of metabolic processes including the TCA 
cycle, oxidative phosphorylation (OXPHOS), biosynthesis of precursors and amino 
acids, fatty acid oxidation, and redox balance. Mitochondrial DNA along with nuclear 
DNA encodes over 100 components involved in OXPHOS. Mutations in any of these 
components can cause IEMs, and suboptimal mitochondrial function can contribute to 
tumorigenesis (Carew et al., 2002).  
Altered Glucose Flux in IEMs and Cancer 
Cancer cells exhibit an interesting metabolic phenotype termed “aerobic 
glycolysis” – wherein they underutilize OXPHOS for ATP generation and convert a 
majority of their pyruvate to lactate, even in the presence of sufficient oxygen. This is 
known as the Warburg effect. It is often accompanied by enhanced flux through the 
pentose phosphate pathway (PPP), increased glycolysis and glutaminolysis. Cancer 
cells are thought to employ the Warburg effect to generate biomass in form of 
nucleotides, proteins and lipids – building blocks for all proliferating cells (Warburg, 
1956, Chandel and DeBerardinis, 2020).  
Interestingly, a number of IEMs also involve metabolic rewiring wherein the PPP 
flux increases along with enhanced glycolysis and glutaminolysis. One such disorder is 
glycogen storage disease Ia (GSD Ia) that is caused by a deficiency in glucose-6-
phosphatase complex (G6PC). G6PC is the last common step between 
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gluconeogenesis and glycolysis. G6PC deficiency causes severe fasting intolerance and 
hypoglycemia, and patients require a constant carbohydrate source to offset this. Loss of 
G6PC diverts glucose-6-phosphate (G6P) generated by glycogen breakdown towards 
glycolysis and PPP, along with increases in lactate production. 75% of GSD Ia patients 
develop liver adenomas while 16% develop HCC (Lei et al., 1993).  
Urea Cycle Disorders and Cancer 
In a similar fashion, urea cycle intermediates are also shunted towards anabolic 
routes in cancer. Altered expression of urea cycle enzymes in cancer reduces nitrogen 
waste generation while simultaneously redirecting carbon and nitrogen to biomass 
generation.  
As discussed earlier, the urea cycle is predominantly involved with ammonia 
removal in the body. However, there has been evidence of this ammonia being 
redirected towards anabolic pathways for amino acid synthesis in breast cancer, 
obviating the need for the urea cycle. The amino acids produced from ammonia 
incorporation include glutamine and glutamate, which are pivotal in cancer cell growth. 
They serve as precursors for biosynthesis of nucleotides, lipids, amino acids, 
antioxidants like glutathione, and maintain TCA anaplerosis. Dysregulation of urea cycle 
components can contribute towards enhanced glutamine utilization, a hallmark of cancer 
cells.  (Erez and DeBerardinis, 2015).  
Carbamoyl phosphate synthase 1 (CPS1) is the first enzyme of the hepatic urea 
cycle (Figure 1). It produces carbomoyl phosphate (CP). CPS1 activity is also contained 
in another enzymatic complex called CAD (CPS2, Aspartate transcarbamylase, 
dihydroorotase). CAD is present in the cytosol, while CPS1 is located in the 
mitochondria. CAD is responsible for pyrimidine synthesis. Recent studies indicate that 
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the differences between mitochondrial and cytosolic pools of CP become blurred in 
cancer cells. CP produced by CPS1 is often redirected towards pyrimidine synthesis in 
lung cancer cells. Unsurprisingly, CPS1 is often over-expressed in lung and colon 
cancers, choliangiocarinomas and some forms of glioblastomas. In these cancers, it is 
associated with aggressive disease status and a poor prognosis. On the other hand, 
CPS1 is downregulated via promoter methylation in HCC. This downregulation is 
accompanied by increased activity of the CAD complex, thereby maintaining enhanced 
pyrimidine synthesis. The next enzyme of the urea cycle – ornithine 
transcarbamoyltransferase (OTC) combines ornithine with CP to form citrulline. 
However, to aid proliferation, lowering OTC levels would help redirect existing CP pools 
towards pyrimidine synthesis. Furthermore, lowered OTC activity will conserve ornithine 
for other biosynthetic fates including polyamines, glutamate and proline production. 
Thus, OTC expression is downregulated in a number of malignancies (Kim et al., 2017). 
Aspartate is a key metabolite in proliferating cells. Cells take it up in miniscule 
amounts from the microenvironment and instead depend on de novo synthesis for their 
aspartate. Intracellular synthesis of aspartate requires a functional TCA cycle, electron 
transport chain (ETC), and healthy mitochondria. Cancer cells often have suboptimal 
TCA cycle and ETC function and thus have limited intracellular pools of aspartate. In a 
setting of uncontrolled proliferation, the cells would divert aspartate towards pyrimidine 
synthesis rather than the urea cycle.  
Aspartate is transported from the mitochondria to the cytosol by citrin. Once in 
the cytosol, it broadly has two key metabolic fates – conversion to argininosuccinate (by 
ASS1) or orotic acid (by the CAD complex). In line with enhanced pyrimidine synthesis, 
proliferating cells would upregulate citrin expression and CAD activity, while 
12 
 
simultaneously downregulating ASS1 expression. Thus, ASS1 downregulation supports 
proliferation by shunting aspartate towards pyrimidine synthesis. This downregulation of 
ASS1 comes with another metabolic vulnerability. Cells lacking ASS1 (and ASL), are 
arginine auxotrophs and depend on exogenous sources for their arginine supply. As a 
result, arginine deprivation has emerged as an attractive therapy in cancers lacking 
ASS1 (and ASL) (Rabinovich et al., 2020, Rabinovich et al., 2016, Keshet et al., 2018, Li 
et al., 2019, Keshet et al., 2020, Nagamani and Erez, 2016, Keshet and Erez, 2018).  
Interestingly, tumors lacking ASS1 exhibit an imbalance in their pyrimidine/purine 
ratio, which in turn leads to a novel surface protein signature. Recent studies indicate 
that such tumors are exquisitely sensitive to immune checkpoint therapy. Regulation of 
ASS1 expression is complex, and diverse factors including MYC, p53, HIF1-a are 
reportedly involved (Lee et al., 2018). However, ASS1 is over-expressed in a few 
malignancies. High ASS1 levels in colon cancer are thought to support arginine 
synthesis and help the cells survive low-nutrient environments.  
Role of ASL expression in carcinogenesis is more ambivalent. High ASL 
expression is considered a poor prognostic factor in breast, liver and colorectal cancers. 
Downregulation of ASL activity is associated with lowered arginine and nitric oxide 
synthesis, which can regulate the immune microenvironment and bolster tumor growth in 
a context depend manner. 
Introduction to clear cell renal cell carcinoma (ccRCC) 
Cancers of the kidney are in the top ten adult malignancies in the United States. 
In 2020, it is estimated that 65,815 new cases of kidney cancer will be diagnosed, and it 
would result in 14,000 deaths. Patients with local disease are offered surgery along with 
standard of care chemotherapy and have a 5-year survival rate of 95%. However, if the 
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disease has metastasized, the survival rate drops to 12%. Renal Cell Carcinoma (RCC) 
is a genetically heterogenous disease with over 17 genes and pathways implicated in 
tumorigenesis. The following table enlists the types of RCC, and their incidence (Linehan 
and Ricketts, 2019) 
Subtype Incidence 
Clear Cell RCC 65-70% 
Papillary RCC 15-20% 
Chromophobe RCC 5-7% 
 
Table 4: Renal Cell Carcinoma Subtypes 
We will focus on the most common subtype – clear cell renal cell carcinoma (ccRCC).  
Genetic and epigenetic landscape of ccRCC tumors 
ccRCC tumors are thus named because of their histological appearance. 
Grossly, they appear yellowish with necrosis and hemorrhage. Histologically, they 
consist of thin walled cells filled with abundant lipids and glycogen – giving the “clear 
cell” appearance. More than 90% of ccRCC tumors exhibit loss of chromosome 3p. A 
copy of the von Hippel Lindau (VHL) gene is located on chromosome 3p, and is 
ubiquitously lost in ccRCC, while the other is mutated or silenced. Other 3p genes that 
are commonly lost in ccRCC tumors are PBRM1 (38%), SETD2 (13.2%), and BAP1 
(11%). It is interesting to note that common tumor suppressive genes like TP53 and Rb 
are mutated in only 11% and <1% of ccRCC tumors, respectively (Mehdi et al., 2017, 
Sato et al., 2013).  
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VHL is a tumor suppressor gene. It encodes for protein pVHL. pVHL is a versatile 
protein that is involved in regulation of glucose metabolism, angiogenesis, cellular 
senescence, apoptosis, WNT signaling, NFkB activity, and suppression of epithelial to 
mesenchymal transition among other activities. It carries out all of its functions by 
recruiting a variety of co-factors and effector proteins. However, the principal function of 
pVHL is its role in degradation of hypoxia inducible factors (HIFs). pVHL along with 
Elongin B, Elongin C, Cul2, and Rbx1 forms an E3 ubiquitin ligase that marks 
hydroxylated HIF subunits for proteasomal degradation under normoxic conditions.  
Hypoxia inducible factors (HIFs) have five variants – HIF1a, HIF2a, HIF3a, 
HIF1b (or aryl hydrocarbon nuclear translocators 1, ARNT1), and HIF2b. HIF1a and 
HIF2a individually form a complex with ARNT1 which translocates to the nucleus and 
initiates a massive transcriptional program. Under normal concentration of oxygen, a set 
of proteins called prolyl hyrdorxylase (PHD), add an -OH group to HIFa subunits. This 
reaction consumes oxygen and thus acts as an oxygen sensor. The hydroxylated HIFa 
subunits are then recognized by and marked for degradation by the pVHL led complex.  
Under hypoxia, PHDs do not hydroxylate HIFa subunits. Thus, HIFa is not 
degraded and accumulates in cells, forms a complex with ARNT1, and translocates to 
the nucleus. Loci of the genome where the HIFa-ARNT1 complex bids are called 
hypoxia responsive elements (HREs). There are hundreds of HREs spread across the 
genome and HIF binding activates a broad transcriptional program in response to low 
levels of oxygen. This includes angiogenic, mitogenic, erythropoietic genes and genes 
that regulate glucose uptake and metabolism. The same outcome is achieved by VHL 
loss – the HIF transcriptional program is activated even in the presence of oxygen. 
15 
 
ccRCC tumorigenesis is centered around the VHL-HIF axis and each event 
represents a distinct step towards malignant transformation. The initiating event is the 
loss of pVHL through mutations and/or epigenetic silencing. This is followed by HIFa 
stabilization and constitutive activation. HIFa activation enhances the transcription of 
genes involved in angiogenesis (like VEGFA), glucose uptake (GLUT1), survival 
(survivin), migration and invasion (CXCR4), and proliferation (EGFR). Thus, HIFa drives 
the tumorigenesis in ccRCC. Of note, only HIF2a has been clearly implicated in ccRCC 
tumorigenesis, the role of HIF1a is ambivalent. Some studies suggest that HIF1a is in 
fact a tumor suppressor and is silenced in ccRCC, while HIF2a is oncogenic. As a result, 
HIF2a has emerged as an attractive therapeutic target in ccRCC (Keith et al., 2012).  
VHL loss alone is not sufficient to drive ccRCC tumorigenesis. Concurrent 
mutations and/or loss in other genes are necessary to achieve that. Fortuitously, in 
ccRCC, chromosome 3p loss deletes three more genes and spurs on tumorigenesis. 
The aforementioned genes are PBRM1, BAP1, and SETD2. Incidentally, all three genes 
are implicated in epigenetic regulation and chromatic modification. Furthermore, they 
have been associated with a number of malignancies including melanoma, 
mesothelioma, pancreatic cancer, colorectal cancer, and leukemia. 
PBRM1 gene encodes for the protein BAF180 which is a part of the chromatin 
remodeling SWI/SNF (switching defective/sucrose nonfermenting) complex. More 
granularly, BAF180 is the chromatin targeting subunit of the polybromo BRG1-
associated factor (PBAF) which in turn is one arm of the SWI/SNF machinery. BAF180 
can bind to acetylated lysines in histone tails through its six tandem bromodomains. The 
recruitment of the SWI/SNF complex to chromatin regulates expression of genes 
involved in DNA replication, transcription, cell death, metabolism and proliferation. In 
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fact, it a key regulator of a large number of transcription factors. Notably, BAF180 is 
known to associate with E-cadherin, thereby modulating cell-cell adhesion and 
movement. Through its interaction with chromatin, BAF180 also confers protection from 
genome instability and aneuploidy.  
Loss or inactivation of PBRM1 results in increased cell growth and migration. 
Conversely, re-expression of PBRM1 in RCC cells causes p21 mediated G1 cell cycle 
growth arrest. Interestingly, re-expression of mutant BAF180 is unable to suppress cell 
proliferation. Furthermore, BAF180 loss in pVHL deficient cells reinforces the HIF 
transcriptional signature. As a result of its critical role in ccRCC tumorigenesis, some 
groups have used PBRM1 loss to model ccRCC disease progression in mouse models 
along with pVHL loss. 
BRCA1 Associated Protein -1 (BAP1) is the protein encoded by the BAP1 gene, 
which is located between VHL and PBRM1 on chromosome 3p. BAP1 mutations are 
observed in uveal melanoma and mesothelioma. Germline BAP1 mutations predispose 
to ccRCC, thus implicating the gene in ccRCC initiation akin to VHL. BAP1 protein is a 
deubiquitylating enzyme of the ubiquitin C-terminal family and it localizes to the nucleus. 
Once in the nucleus, BAP1 forms a complex with breast cancer type 1 susceptibility 
protein (BRCA1) and BRCA1-associated RING domain protein 1 (BARD1) and is 
involved in critical functions of DNA repair and cell cycle regulation. BAP1 regulates the 
G1/S transition and its loss aids uncontrolled proliferation. The exact role of BAP1 loss in 
ccRCC is as yet unclear. However, BAP1 loss is associated with activation of a number 
of growth pathways like the epidermal growth factor (EGF), nerve growth factor (NGF), 
insulin, PI3K, and mTORC1 pathways. 
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SETD2 is the fourth gene residing on chromosome 3p that is frequently lost in 
ccRCC tumors. It encodes a H3K36 histone methyltransferase. Chromatin wide 
reduction in the H3K36me3 histone mark is associated with SETD2 loss. H3K36me3 is 
critical for activation of ATM and TP53 mediated DNA damage responses and SETD2 
loss interferes with these responses. Thus, SETD2 loss causes aberrations in the repair 
of DNA double-strand breaks, mismatch repair and ultimately leads to genomic 
instability. Interestingly, the H3K36me3 mark is also associated with heterochromatin 
and SETD2 loss is thought to alter chromatin accessibility and affect RNA splicing in 
ccRCC tumors. 
Lysine Demethylase 5C (KDM5C) is a gene present on the X chromosome and is 
mutated in 7-9% of ccRCC tumors. H3K4me3 marks are linked to actively transcribed 
chromatin. KDM5C demethylates these marks and interferes with the transcription of 
certain genes. Interestingly, HIF turns on KDM5C expression, and KDM5C in turn 
represses the expression of a number of other HIF targets. Thus, in the context of 
constitutive HIF activity, KDM5C might act as a modulator and regulate HIF target gene 
expression in a tumor suppressive manner. KDM5C knockdown in VHL deficient cells 
accelerates ccRCC tumorigenesis. Furthermore, KDM5C is broadly involved in 
maintaining heterochromatic sites and stability of the genome, and its deficiency tips 
cells towards malignant transformation. 
Another demethylase, lysine demethylase 6A (KDM6A), is also located on 
chromosome X and is mutated in 1% of ccRCC tumors. KDM6A interacts with the 
polycomb complex and together are involved in the repression of certain genes. 
Mutations in KDM6A alter expression of these repressed genes and promote 
proliferation. However, the exact mechanisms for this remain unknown. 
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Both KDM5C and KDM6A escape X-inactivation and belong to a group of genes 
called EXITS (Escape from X-inactivation Tumor Suppressors). Their homologs are 
present on the Y chromosome and are also downregulated in 40% of the male ccRCC 
patients due to Y chromosome deletion. Frequent mutations and deletions in these 
genes allude to a significant role in ccRCC growth (Hakimi and Voss, 2018, Ricketts et 
al., 2018). 
Metabolic landscape of ccRCC 
ccRCC is often referred to as a metabolic disorder, owing to its widespread 
metabolic rewiring. A vast majority of these changes have been attributed to VHL loss 
and HIF stabilization, with HIFs being the driving force behind the altered metabolic 
landscape. In this section I will briefly summarize the altered metabolic pathways in 
ccRCC tumors (Wettersten et al., 2017, Hakimi et al., 2016, Clark et al., 2019, Yong et 
al., 2020, Courtney et al., 2018, Li et al., 2014). 
Glucose is an important fuel for a variety of cells types. Under normoxia, non-
transformed cells convert glucose to pyruvate which in turn enters the TCA cycle and 
ETC to produce ATP. In the absence of oxygen, cells switch to anaerobic glycolysis 
converting pyruvate to lactate in a reaction catalyzed by lactate dehydrogenase (LDH). 
However, cancer cells – especially ccRCC cells, rely on lactic acid fermentation 
irrespective of the oxygen levels. This has been attributed to HIFs driving increased LDH 
expression. Recent tracing experiments in ccRCC patients have demonstrated the 
complete dependence of ccRCC cells on aerobic glycolysis, thus being completely 
Warburg-ian, unlike other malignancies. ccRCC tumors also exhibit increased levels of 
the glucose transporter 1 (GLUT-1) along with a number of glycolytic enzymes including 
phosphoglycerate kinase, hexokinase, pyruvate kinase, pointing towards enhanced 
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glycolysis. This uptick in glycolysis is accompanied by the downregulation of 
gluconeogenesis as evidenced by the loss of enzyme fructose bis phosphatase 1 
(FBP1). FBP1 expression promotes gluconeogenesis in the cytosol, whereas nuclear 
FBP1 prevents HIF-DNA binding, hindering HIF target transcription. Thus, FBP1 loss in 
ccRCC tumors has a two-fold advantage – dampening gluconeogenesis and permitting 
HIF mediated transcription. Increased GLUT-1 expression might aid immune 
suppression in ccRCC, as tumor cells consume more glucose, effectively starving 
infiltrating CD8 T-cells. 
The TCA cycle is selectively altered in ccRCC tumors – it is downregulated 
between succinate and malate and upregulated between citrate and a-ketoglutarate 
when compared to the normal kidney. Additionally, reductive carboxylation is 
upregulated in ccRCC tumors presumably to aid increases in fatty acid synthesis. 
ccRCC tumors increase their glutamine uptake to fuel this enhanced fatty acid synthesis. 
HIF2a expression has been shown to be sufficient to drive this glutamine addiction and 
TCA cycle alteration. 
In addition to fueling fatty acid synthesis, increased glutamine uptake also 
contributes to the glutathione pathway. ccRCC tumors have increased levels of reactive 
oxygen species (ROS), and increased glutathione production serves as an internal ROS 
scavenger. Studies suggest that glutamine withdrawal has detrimental effects on ccRCC 
growth. 
Altered lipid metabolism is a hallmark of ccRCC tumors. Increased glutamine 
uptake and enhanced reductive carboxylation together drive flux towards fatty acid 
synthesis. As a result of this, ccRCC cells have increased levels of cholesterol esters 
when compared to the normal kidney. In line with this finding, ccRCC tumors have 
20 
 
enhanced levels of lipid synthesis enzymes – stearoyl-CoA desaturase 1 (SCD1) and 
fatty acid synthase (FAS). It is postulated that these lipids are stored to aid membrane 
synthesis. Additionally, ccRCC patients have increased levels of acyl carnitines and 
carnitines. Although their effect on ccRCC progression is unclear, they can serve as 
biomarkers for diagnosis. 
Tryptophan metabolism is another altered pathway in ccRCC tumors. Tryptophan 
is an essential amino acid. It is involved in three critical metabolic pathways – the 
indoleacetate pathway, the serotonin pathway, and the kynurenine pathway. In ccRCC 
tumors, the indoleacetate and serotonin pathways are downregulated in favor of the 
upregulated kynurenine pathway. Combining kynurenine pathway blockade with anti-PD-
1 therapy is currently under clinical trials. 
Pentose pathway serves as a shunt to glycolysis that diverts glucose-6-
phosphate towards ribose sugar synthesis. Glucose-6-phosphate dehydrogenase is the 
rate-limiting enzyme in this pathway and enhanced G6PD levels has been reported to be 
protective in kidney disease. ccRCC tumors have increased flux through PPP perhaps 
for its tissue specific protective advantages. Additionally, G6PD activity also promotes 
cellular proliferation. 
Animal models in ccRCC 
Development of a genetically engineered mouse model (GEMM) for ccRCC has 
been an ongoing challenge for researchers. Loss of VHL, the driver event in ccRCC, 
does not result in tumorigenesis in mice, thus highlighting the need for a “second-hit”. 
SETD2, PBRM2, and BAP1 are the other top three altered genes in ccRCC. They all 
reside on chromosome 3p along with VHL – thus modeling loss of 3p would serve as a 
good strategy for ccRCC. However, in mice Vhl is on chromosome 6, Setd2 on 
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chromosome 9, and Pbrm1 and Bap1 on chromosome 14 – making modeling 
substantially more complex. Thus, modeling human ccRCC progression in mice has not 
been very fruitful (Wolf et al., 2020). 
Nargund et al. employed the Ksp-Cre system to conditionally delete Vhl and 
Pbrm1 in the renal epithelium (Nargund et al., 2017). In this model the mice developed 
polycystic kidney disease (PKD) by 6 months of age and 50% of them developed tumors 
by 10 months. The tumors resemble human ccRCC tumors with the clear cytoplasm, HIF 
activation and mTOR involvement. On the other hand, Gu et al. developed a Vhl and 
Pbrm1 conditional knockout model with paired box gene 8 (Pax8) as the driver Cre. 85% 
of the mice developed tumors by 9 months of age and the tumors resembled human 
ccRCC tumors with PBRM1 loss. 
BAP1 is mutated in 10-15% of ccRCC cases and combining BAP1 loss with VHL 
loss has been tried out for ccRCC model development. Simultaneous deletion of Bap1 
and Vhl with Six2 (a nephron progenitor transcription regulator) as a Cre driver led to 
ccRCC development, but the pups died within a month. Utilizing Pax8 as the driver Cre 
to delete Vhl and heterozygously alter Bap1 resulted in ccRCC-like tumors with the 
“clear cell” histology (Gu et al., 2017). 
A common alteration in ccRCC tumors is MYC activation. Combining Vhl loss 
with doxycycline induced c-MYC activation along with deletion of a tumor suppressor 
gene CDKN2A (INK4A/ARF), Bailey et al. generated three different mouse models. C-
MYC activation alone produced papillary RCC (pRCC) like tumors, while c-MYC 
activation plus Vhl loss resulted in tumors with ccRCC features. Finally, the combination 
of c-MYC activation, Vhl loss, and Cdkn2a deletion resulted in an aggressive ccRCC 
phenotype with liver metastasis in 30% of the mice. Although an excellent model to 
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study aggressive disease, only 6% of ccRCC patients report alterations in these genes 
(Bailey et al., 2017). 
Employing single nucleotide mutations in other common tumor suppressor 
genes, Rb and Tp53, along with Vhl loss, Harlander et al. developed a ccRCC model. 
More than 80% of these triple-mutant mice developed tumors in 25-61 weeks, with each 
mouse averaging 5 tumors, and males getting more tumors than females (Harlander et 
al., 2017). 
SETD2 mutant models have not been developed yet. Similarly, comprehensive 
analysis of the tumor microenvironment, and drug responses has not been carried out in 
these GEMMs. Furthermore, these models use Cre drivers to delete genes during 
embryonic development. There is an unmet need to develop models that can trigger 
sequential deletions in adult mice to better model the natural progression of human 
ccRCC.  
As a work around for complex GEMM development, the field has utilized 
xenograft models of ccRCC. These involve injecting ccRCC cells orthotopically in the 
renal capsule or subcutaneously in immunocompromised mice. Xenograft and patient 
derived (PDX) models have been shown to maintain histology, gene expression, copy 
number variations, and mutagenic profiles as patient tumors. However, they fall short in 
studies relating to immune responses, tumor microenvironment and extra-cellular matrix 
modeling. Nonetheless, they serve as a great tool to assess genetic alterations, and 
drug responses in ccRCC.  
Therapeutic landscape of ccRCC 
ccRCC treatment depends on the stage of the disease at diagnosis. For early 
stage I/II ccRCC localized to one kidney, surgery has been the most effective option. 
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This generally involves either radical or partial nephrectomy contingent on the extent of 
the spread. Surgery is not followed by adjuvant chemotherapy. As mentioned earlier, 
patients with localized disease have high 5-year survival rates. The same is not true for 
metastatic disease. Surgery is also not a viable option after the disease has spread. 
Furthermore, ccRCC tumors are resistant to radiation and traditional chemotherapy with 
response rates being between 0-10%. Typically, ccRCC tumors were treated with 
cytokines, while other forms of chemotherapy resulted in dismal responses coupled with 
severe adverse events (Huang and Hsieh, 2020).  
Interleukin-2 (IL-2) is produced by activated CD4+ T cells and leads to 
differentiation of T cells to helper T1 and T2 cells. Furthermore, it induces CD8+ T-cell 
and natural killer cell cytotoxic activity. Exogenously provided recombinant IL-2 is 
thought to boost cytotoxic activity in the tumor microenvironment and help treat the 
tumors. IL-2 treatment was approved in 1992 and provided modest benefits over 
radiation and traditional chemotherapy. However, only 7-10% of the patients have 
complete and durable responses for up to 20 years after the initial treatment. A majority 
of the patients are partial responders and often relapse. Over 85% of the patients have 
adverse side effects including but not limited to anemia, respiratory distress, and 
arrhythmias.  
Interferon Alpha (IFN-a), a cytokine, enhances natural killer cell activity along 
with macrophage and dendritic cell responses and helps boost antitumor immunity. 
However, only 6-15% of patients achieved partial responses, while less than 5% had 
complete remission. Broadly, IFN-a  was better tolerated than IL-2 and is being 
investigated further in combination trials. 
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Before 2004, cytokine treatment, albeit ineffective, was the mainstay of ccRCC 
treatment. The poor responses and high toxicities led researchers to explore other 
therapeutic avenues. VHL drives ccRCC tumorigenesis and also leads to activation of 
vascular endothelial growth factor (VEGF) – a proangiogenic factor. Interestingly, ccRCC 
tumors are densely vascular thus, making them an excellent target for anti-VEGF 
treatment. A plethora of VEGF inhibitors have been approved for ccRCC treatment. In 
addition to their anti-angiogenic properties, these drugs also target other growth factors 
such as the platelet-derived growth factor receptor. Anti-VEGF treatment leads to 
normalization of the tumor vasculature and promotes antitumor immunity by enhancing 
tumor accessibility. 
Sorafenib was the first targeted treatment approved for ccRCC. However, it only 
marginally improved long-term outcomes when compared to IFN-a  treatment as a first-
line therapy. It fared better in a second-line setting, significantly increasing progression 
free survival. Sunitinib, another monoclonal antibody therapy, showed partial responses 
in 34% of patients and was significantly less toxic than cytokine therapy. Additionally, it 
improved progression free survival (PFS) from 5 months (IFN-a) to 11 months. Thus, 
sunitinib was recommended for first-line treatment in ccRCC. 
Bevacizumab, an VEGF inhibitor, when combined with IFN-a showed remarkable 
results (10.2 vs 5.4 months PFS) when compared to IFN-a alone. However, the patients 
also experienced higher incidences of adverse events. Another inhibitor, pazopanib 
improved survival in treatment naïve patients (11.1 months vs 2.8 months) with median 
response duration of 1 year. It also had significantly lower adverse events and better 
quality of life compared to sunitinib. Pazopanib is preferred over sunitinib for first-line 
therapy. More recently, axitinib has been approved as a second-line therapy after 
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sunitinib or sorafenib and has showed improved survival. Current trials involve axitinib 
dose escalation in treatment naïve patients and combination therapies. 
Another dysregulated pathway is mTORC1 signaling, making it an attractive 
target for treatment.  Rapa-logs like temsirolimus and everolimus are used to target 
mTORC1 and inhibit its formation. Temsirolimus modestly improved survival over IFN-a  
but had a poor toxicity profile. It failed to improve survival in a second-line setting. 
Everolimus, on the other hand, excelled in the second line setting after failure with 
sunitinib or sorafenib, almost doubling PFS and being well-tolerated.  
About 1/3rd of RCC tumors express programmed death-ligand 1 (PD-L1), while 
over 50% of the tumor infiltrating immune cells express PD-1. Thus, RCC tumors are a 
suitable candidate for immune checkpoint inhibitors. There are two main categories – 
anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1/PD-L1 inhibitors. 
CTLA-4 inhibits T-cell activation and blocking CTLA-4 enhances antitumor immunity. 
Similarly, PD-1/PD-L1 cascade downregulates T-cell activation, and its inhibition 
reduces immunosuppression in tumors. 
PD-1 inhibitor, nivolumab, improved overall survival from 19.6 months 
(everolimus) to 25 months in patients that had failed first line treatment with an 
antiangiogenic agent. Patients receiving nivolumab also experienced fewer side effects. 
Combining nivolumab with ipilimumab (CTLA-4 inhibitor) resulted in increased overall 
survival when compared to sunitinib. Furthermore, poor to median risk patients receiving 
the combination therapy experienced fewer adverse effects, had a better quality of life, 
and had a higher rate of complete responses that sunitinib alone. 
Tyrosine kinase receptor inhibitors (TKIs) are another class of drugs approved for 
RCC treatment. Cabozantinib, a MET and AXL receptor tyrosine kinase inhibitor that 
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also blocks VEGF activity, was approved for second-line therapy in RCC. It improved 
survival over everolimus alone, but had similar toxicity. Another TKI targeting VEGF, 
Lenvatinib when combined with everolimus almost triples the PFS (14.6 months vs 5.5 
months) when compared to everolimus alone. However, the combination is extremely 
toxic and hence the risk/benefit ratio needs to be carefully assessed.  
Combination therapy has been proving to be effective in RCC. In 2019, axitinib 
along with pemnrolizumab (anti PD-1 antibody) got approved for therapy. This 
combination improved 12-month survival in 90% of the patients when compared to 78% 
in sunitinib treated patients. However, there was an increase in adverse events as well. 
Similarly, combining axitinib with avelumab (anti PD-L1 antibody) resulted in higher PFS 
when compared to sunitinib with comparable toxicities. In both these studies, PD-1 or 
PD-L1 expression in the tumor did not affect the final outcome. 
Treatment for ccRCC has gone through a sea of change in the past two decades. 
Enhancing effectivity while controlling adverse effects and maintaining a good quality of 
life have been the tenets of drug discovery for ccRCC. Despite the progress made, there 
is an unmet need to develop novel treatment options that can be effective in a majority of 
the patients and provide long lasting remissions. Knowledge of ccRCC metabolism can 
aid drug discovery and alter the therapeutic landscape. 
Main Hypothesis and Objectives 
The objective of my thesis work has been to elucidate the role of urea cycle 
enzymes in clear cell renal cell carcinoma (ccRCC) progression. Since these enzymes 
are almost universally under-expressed in ccRCC, the main aim of this endeavor was to 
investigate the pro-proliferative benefit provided by urea cycle downregulation. To 
address this question, I broke down the study into two spatially distinct sets of enzymes 
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– the mitochondrial arginase 2 (ARG2) and the cytosolic argininosuccinate synthase 1 
(ASS1), and argininosuccinate lyase (ASL). I employed a variety of in vitro and in vivo 
proliferation assays to ascertain the effect of enzyme loss in normal renal cells, and 
enzyme re-expression in ccRCC cells. Loss of urea cycle enzymes promotes growth in 
normal kidney cells, while their re-expression suppresses growth in ccRCC cells. 
Furthermore, I used mass spectrometry based steady-state and labeled substrate 
measurements of metabolites to expand on the mechanistic underpinnings of this 
suppression. Finally, based on the metabolic landscape of ccRCC tumors, I attempted to 
rescue the growth suppression induced by enzyme re-expression either with a co-factor 
(PLP, ARG2) or with nucleosides (cytidine and thymidine, ASS1+ASL).  
 In Chapters 2 and 3, I explore these questions further, while in chapter 4 I 




Chapters 2 and 3 have been adapted from the following articles: 
Ochocki, J. D., Khare, S., Hess, M., Ackerman, D., Qiu, B., Daisak, J. I., ... & Li, B. 
(2018). Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor 





Khare S., Lobel G., Kim L., Lee P., Keith B., Simon MC. (in preparation). 
Argininosuccinate synthase 1 and argininosuccinate lyase suppress growth in clear cell 
renal cell carcinoma by depleting cellular aspartate and altering pyrimidine synthesis. 
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CHAPTER 2: METHODS AND MATERIALS 
Experimental Model and Subject Details 
Mice 
Xenograft tumor experiments were approved by the Animal Care and Use 
Committee at the University of Pennsylvania. Female NIH-III nude mice (Charles River, 
6-8 weeks) were injected subcutaneously into each flank with 5 million ccRCC cells in a 
1:1 mixture of PBS and Matrigel (Corning 356234) with an injection volume of 200 μL. 
Once palpable tumors were established, tumor volume was monitored by caliper 
measurements. For doxycycline induced expression of enzymes, xenograft injections 
were performed as above, and tumors were allowed to grow till 200mm3 before switching 
the diet to a dox containing chow (200mg/kg). Upon completion of the experiment, the 
animals were sacrificed by CO2 inhalation and xenograft tumors were dissected for 
downstream analyses.  
Cell lines and Cell Culture Conditions 
Authenticated (short tandem repeat profiling) human cell lines HK-2, 786-O, 769-
P, A498, RCC4, RCC10, UOK101, and UMRC2 were obtained from the American Type 
Culture Collection. RCC10 was a kind gift from W. G. Kaelin (Dana Farber Cancer 
Institute, Boston, MA). Cells were cultured for a maximum of 4 weeks before thawing 
fresh, early passage cells. All cells are routinely confirmed to be Mycoplasma negative 
(MycoAlert; tested every 3 months). ccRCC cells were cultured in DMEM containing 
10% FBS and Pen/Strep while HK-2 proximal tubular epithelial cells were cultured in 
Keratinocyte-SFM medium supplemented with human recombinant epidermal growth 
factor and bovine pituitary extract. To mimic tumor microenvironmental O2 levels, 786-O 
cells were grown under hypoxia. Hypoxic conditions (0.5% O2) were achieved in a 
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Ruskinn in vivo2 400 workstation, by supplementing ambient air with balanced N2 and 
CO2. HK-2 cells don’t survive 0.5%-1% O2 beyond 48 hours; therefore, 1% FBS and 1 
mM glucose culture conditions were employed to mimic microenvironmental stress 
typical of renal tumors. For arginine labeling assays, cells were maintained in arginine-
free DMEM supplemented with 10% dialyzed FBS and 398.1 μM 15N4-arginine (standard 
DMEM arginine concentration). Similarly, for labelled glucose and glutamine studies, 
cells were cultured with the labelled substrate for 24 hours (10mM U-13C6- D- glucose, 
low serum, 4mM glutamine) and 3 hours (4mM 15N2 L-glutamine, low serum, 1mM 
glucose). For low-glucose conditions, cells were incubated in glucose-free DMEM 
supplemented with 1 mM glucose.  
Constructs and Viral Transduction 
Lentivirus was produced by transfecting HEK-293T cells with the indicated 
expression plasmid, pRSV-Rev, pMDL, and pCMV-VSV-G plasmids (4th generation 
lentiviral system) using Fugene6 transfection reagent (Promega). The virus was 
harvested 48 hours after transfection. For viral transduction, cells were incubated with 
medium containing virus 24 hours. Cells were allowed to recover for 24 hours before 
antibiotic selection, and surviving pools were utilized for downstream analyses (with the 
exception of clonally selected HK-2 cells, detailed below). 
The lentiviral vector pLKO.1 Scramble (plasmid no. 17920) was obtained from 
Addgene. pLKO.1 lentiviral vector expressing hairpins against ARG2 SH-1 
(TRCN0000051018), ARG2 SH-2 (TRCN0000051020), ASS1 SH-3 
(TRCN0000045554), ASS1 SH-4 (TRCN0000045553), ASL SH-4 (TRCN0000078308), 
and ASL SH-5 (TRCN0000078309) were obtained from The RNAi Consortium (TRC) at 
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the Broad Institute and GE Dharmacon. For genetic knockout using CRISPR/Cas9, the 
lentiviral vector lentiCRISPR v2 was obtained from Addgene (plasmid no. 52961). Guide 
RNA’s (sgRNA’s) were cloned into this plasmid and single knockout clones were 
screened and selected following previously established methods (Sanjana et al., 2014). 
The sgRNA sequences that were positive for the desired knockout were as follows: 
ARG2 (caccgGAAGAAATCCGTCCACTCCG and the complementary strand 
aaacCGGAGTGGACGGATTTCTTC), ASS1 (caccgCAGCCACACGAGGATGCACG and 
the complementary strand aaacCGTGCATCCTCGTGTGGCTG) and ODC1 
(caccgGAAGGGGCTTTACATGTGCG and complementary 
aaacCGCACATGTAAAGCCCCTTCC). 
Sequence verified cDNA constructs were obtained from the Mammalian Gene 
Collection (GE Dharmacon) and were subcloned into the pCDH-CMV-MCS-EF1-
Puromycin mammalian expression vector (System Biosciences CD510B-1). Stable cell 
line generation with multiple cDNA’s was achieved using either of two additional 
mammalian expression vectors with different selectable markers: pCDH-CMV-MCS-
Hygromycin or pCDH-CMV-MCS-Neomycin (System Biosciences). ARG2 cDNA 
construct: MHS6278-202800846. ASS1 cDNA construct: MHS1010-202694229. OAZ1 
cDNA construct: MHS6278-202858287. ASL cDNA construct: MHS6278-202755499. 
The ARG2 (H160F) mutant was generated using Stratagene’s QuikChange II 
mutagenesis kit (Agilent). pLJM1-Flag-RagBGTP-Q99L mutant plasmid was obtained from 
Addgene (plasmid no. 19315) and subcloned into pCDH-CMV-MCS-Neomycin (System 
Biosciences). The cDNA for human excitatory amino acid transporter 1 (hEAAT1) was 
obtained from Addgene (plasmid no. 32813) and was subcloned into pCDH-CMV-MCS-
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Neomycin. Constitutive mTORC1 constructs were a kind gift from David Sabatini 
(Addgene plasmid no. 69015 and 69006). These constructs were subcloned into pCDH-
CMV-MCS-Puromycin or hygromycin. 
Western Blot Analysis 
Cells were harvested in lysis buffer (40 mM HEPES pH=7.4, 2 mM EDTA, 10 mM 
pyrophosphate, 10 mM glycerophosphate, 1% Triton X-100) containing Roche complete 
ultra-protease/phosphatase inhibitor (cat. 05892791001). For western blots of xenograft 
tissue, approximately 5-10 mg of tissue was suspended in 500 μL lysis buffer and 
homogenized on ice using a Tissue-Tearor (Biospec, 985370). Samples were 
centrifuged at 20,000 g for 15 min at 4°C. Protein lysates were resolved by Tris-Glycine 
SDS-PAGE and were transferred to nitrocellulose membranes (Biorad #162-0115, 0.45 
μm pore size for all experiments, except when probing for 4E-BP1 when 0.2 μm pore 
size was used). All membranes were incubated with the indicated primary antibodies 
overnight at 4°C and were diluted in TBST (20 mM Tris, 135 mM NaCl, and 0.02% 
Tween 20) supplemented with 5% bovine serum albumin. Primary antibodies were 
detected with horseradish peroxidase-conjugated secondary antibodies followed by 
exposure to ECL reagents, except ARG2, ASS1, and ASL which were incubated with 
fluorescently conjugated secondary antibodies and detected on the Li-COR Odyssey 
CLx imaging system.  
TCGA RNA-seq Analysis 
Level 3 RNA-seq data for ccRCC and normal kidney samples were downloaded 
and analyzed from the TCGA as previously described (Li et al., 2014). Briefly: differential 
gene expression analysis of tumor and normal samples was performed using DeSeq 
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(Bioconductor Version 2.12). Normalized counts, P values, false discovery rate, adjusted 
P values (p-adj), and fold expression change for each gene were exported. To perform 
the gene set analysis, a comprehensive list of 2,752 genes encoding all known human 
metabolic enzymes and transporters were clustered into functional sets according to the 
metabolic pathways annotated by the Kyoto Encyclopaedia of Genes and Genomes 
(KEGG) (http://www.genome.jp/kegg/). The cut-off value of p-adj was set to 0.1 to 
exclude genes not consistently detected by RNA-seq. Survival analysis of the data was 
performed in GraphPad Prism and statistical effects were analyzed using the log-rank 
(Mantel-Cox) test.  
Immunohistochemistry 
Normal and ccRCC kidney tissue sections (from Cooperative Human Tissue 
Network) and tissue microarray slides (KD802, KD804, KD481, KD482, KD244, KD901, 
KD601, KD70, KD1503, KD601 from US Biomax) were deparaffinized by baking slides 
at 50°C for 20 min. The slides were rehydrated in series of ethanol solutions and 
endogenous peroxidase activities were quenched by 1% H2O2 in distilled water for 30 
min. After three washes in TT buffer (500 mM NaCl, 10 mM Trizma, and 0.05% Tween-
20), antigen retrieval was performed by boiling slides for 20 min in a citrate-based 
antigen unmasking solution (Vector Labs, H3300). After cooling down to room 
temperature, slides were blocked in 2% normal goat serum and 4% BSA in Tris buffer 
with Tween 20 and then blocked with avidin and biotin solutions (Vector Labs, SP-2001). 
Next, tissue slides were incubated with various primary antibodies at 4°C overnight. After 
three washes in TT buffer, biotinylated secondary antibody was added onto these slides 
for 1 hour. Sections were then processed using the Vectastain Elite ABC Kit (Vector 
Labs, PK-6100) and DAB peroxidase substrate kit (Vector Labs, SK-4100), dehydrated 
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in a standard ethanol/xylenes series, and mounted in 75% v/v Permount (Fischer, SP15-
500) in xylenes. 
Immunofluorescence 
Immunofluorescence of mTOR in 786-O ccRCC cells was conducted as 
previously described (Clippinger and Alwine, 2012). Briefly: cells were plated in 35 mm 
dishes in which a 12 mm coverslip was placed on the bottom. After 24 hours, the cells 
were washed three times with PBS and fixed for 20 min in 4% paraformaldehyde at 
room temperature. Cells were permeabilized in PBS containing 0.5% Triton X-100 and 
blocked in PBS containing 5% bovine serum albumin (blocking buffer). Primary 
antibodies against mTOR (Santa Cruz, sc1549) and LAMP (BD Biosciences, 555803) 
and secondary antibodies (Alexa Fluor 594 and Alexa Fluor 647, Invitrogen) were diluted 
in blocking buffer. Coverslips were washed three times in PBS, rinsed in H2O, and 
mounted on slides using VectaShield mounting medium containing 4′6′-diamidino-2-
phenylindole (DAPI) (Vector Laboratories). Slides were examined using a Nikon Eclipse 
E600 (40x objective) microscope, and pictures were taken using a Hamamatsu camera. 
Quantitative RT-PCR 
Total RNA was isolated using the RNA easy purification kit (Qiagen, 74104). 
cDNA was synthesized using a High Capacity RNA-to-cDNA kit (Applied Biosystems, 
4368814). qRT-PCR was performed on a ViiA7 Real-Time PCR system from Applied 
Biosystems. Predesigned Taqman primers were obtained from Life Technologies for the 
following genes: ACTB (HS01060665_G1), 18S (HS03928985_G1), ASS1 
(HS01597989_G1), ARG2 (HS00982833_M1), and ASL (Hs00902699_M1). 
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Anchorage-independent growth assay 
ccRCC cells stably expressing ARG2, ASS1, ASL, PDXK, or vector control were 
plated at a density of 6,000 cells per well (using 6-well plates) in complete DMEM 
containing 0.3% agarose (low-melt 2-hydroxyethylagarose, Sigma Aldrich A4018), onto 
underlays composed of DMEM containing 0.6% agarose. Additional media was added to 
the cultures once per week, and after three weeks of growth the colonies were 
quantified. Similar experiments were performed for HK-2 cells and ccRCC cells with 
knockdowns. 
Liquid-overlay spheroid growth assay 
Three-dimensional spheroid cultures were generated using a liquid overlay 
technique as previously described (Khaitan et al., 2006). Briefly: Twenty-four–well plates 
were coated with 1% agarose in DMEM before plating 100,000 cells per well in DMEM 
plus 10% FBS. To promote spheroid formation, plates were swirled before incubation. 
Media were changed every 2 days, and spheroids were harvested and measured after 9 
days. Measurement of spheroid volume was conducted using ImageJ software by 
measuring two orthogonal diameters and calculating the geometric mean radius, given 
by , where r is the radius and d1 and d2 represent the measured diameters. 
Spheroid volume was calculated as  . To calculate the number of cells per 
spheroid, 12 spheroids were pooled and dissociated with accutase for 10 min at room 
temperature. After centrifugation, the cells were counted with a hemocytometer; the 
count was divided by 12 to get the average number of cells per spheroid and this 








Matrigel-based spheroid growth assay 
Matrigel- based 3D spheroids were generated using a technique previously 
described in (Lewis et al., 2015; Vinci et al., 2012). Briefly: 3000 cells per well were 
plated in a 96-well “low adherence” plate along with DMEM plus 10% FBS and 2.5% 
matrigel. Plates were centrifuged at 1700 rpm to promote spheroid formation, and then 
imaged every two days for two weeks using the EVOS FL Auto Imaging System. 
Spheroid volume was calculated using a previously published ImageJ macro (Ivanov et 
al., 2014). 
Cell Growth Assays 
Cell growth assays were performed with either standard counting or using WST-1 
reagent. For standard counting: multiple cultures of HK-2 or ccRCC cells were plated in 
6 cm dishes at 50,000 cells/plate (ccRCC) or 100,000 cells/plate (HK-2) in complete 
DMEM. For growth assays performed in low-glucose and low-serum conditions, cells 
were maintained in glucose-free DMEM supplemented with 1% dialyzed FBS and 1 mM 
glucose. Each day, one set of culture plates was collected and counted. For WST-1 
growth assays: HK-2 or ccRCC cells were plated in 96-well plates at 500 cells/well 
(ccRCC) or 1,500 cells/well (HK-2) and allowed to attach overnight (1 - 96-well plate for 
each day of the assay). The following day, the media was changed with 200 μL of 
complete DMEM supplemented with assorted small molecules (e.g. putrescine, arginine, 
ornithine, etc.), depending on the assay (see figures for exact concentrations used in 
each experiment). The cells were subjected to WST-1 (Sigma Aldrich, 11644807001) 
assay following manufacturers protocols; this was considered Day 0. This was repeated 
for each day of the assay and the data in each experiment were normalized to the 
starting cell number at Day 0 of the assay.  
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For polyamine toxicity studies, we estimated the concentration of putrescine per 
cell using our data and published values for cell doubling time and the per cell volume 
(National Cancer Institute Developmental Therapeutics Program, NCI-60 Cell line Data: 
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.html) and protein content 
(Dolfi et al., 2013). With these estimations, we determined that normoxic 786-O vector 
control cells contain approximately 3.3 mM putrescine per cell, and that ARG2 re-
expression increased this by approximately 25% to 4.5 mM/cell. Hypoxia increases the 
uptake of exogenous putrescine, and accordingly we found that hypoxic 786-O vector 
control cells contain approximately 6.7 mM putrescine/cell, twice the amount under 
normoxia.  ARG2 expression raised the levels even further to 8.2 mM/cell in this setting. 
It is important to note that these calculations are estimates based on literature values of 
cell volume and protein content per cell. Nonetheless, we feel it provides an adequate 
estimation of the putrescine content per cell, which justifies treating cells with 1-10 mM 
putrescine, spermine, and spermidine.  
Arginase Activity Assay 
Arginase activity was determined using the Abnova Arginase Activity Assay Kit 
(KA1609) following manufacturers protocols. Briefly: 786-O ccRCC cells expressing 
empty vector, ARG2 wild type, or ARG2 H160F were lysed in lysis buffer (see western 
blot analysis section for recipe), which was used directly in the assay. A urea standard 
curve was made, and the samples were mixed with assay buffer and incubated for 1 
hour at room temperature, after which the absorbance was read at 430 nm to quantify 
the urea produced. Data were normalized to protein concentration in each sample.  
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Urea concentration was measured in 786-O xenograft tissues using the BioVision 
Urea Colorimetric Assay Kit K375-100 following manufacturers protocols.  
Metabolomics Analysis 
Mass spectrometry–based metabolomics analysis of primary ccRCC was 
performed with Metabolon, as previously described (Li et al., 2014). Additionally, 
unbiased metabolomics analysis of 786-O ccRCC xenograft tissue expressing either 
empty vector or ARG2 was performed with Metabolon, in the same manner as (Li et al., 
2014).  
Arginine, Citrulline, and Aspartate Measurement via LC/MS 
786-O ccRCC cells expressing empty vector, ARG2, and/or ASS1 were cultured 
for 24 hours, washed, and quenched by the direct addition of 1 mL −80°C 4:1 
methanol:water (v/v) to the cell culture dish. Plates were placed at −80°C for 20 min, 
scraped, and transferred into Eppendorf tubes. Samples were pulse sonicated on ice for 
30 seconds at a rate of 1 pulse/sec prior to centrifugation at 16,000 × g at 4°C for 10 
minutes. The supernatants were then transferred to clean glass tubes and evaporated to 
dryness under nitrogen. Dried residues were resuspended in 100 μL of mobile phase A 
(5 mM ammonium acetate in water) for LC/MS analysis, which was conducted as 
previously described (Aird et al., 2015). 
15N-Arginine Metabolite Tracing 
Prior to metabolic labeling assays, cells were maintained in SILAC Flex arginine-
free DMEM (A24939-01) supplemented with 10% dialyzed FBS and 398.1 μM arginine 
(standard DMEM concentration). This media also lacks glucose, phenol red, glutamine, 
and lysine, which were added back to standard DMEM concentrations (25 mM, 15.0 
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mg/L, 4.0 mM, and 0.798 mM, respectively). For labeling studies, HK-2 cells were plated 
in 10 cm dishes in low glucose (1 mM) and low serum (1%) conditions (SG) and 
incubated for 48 hours prior to changing the media to SILAC Flex SG media 
supplemented with 398.1 μM 15N4-arginine, which was then incubated for 24 hours. 786-
O cells were plated in 10 cm dishes in complete SILAC Flex DMEM and placed under 
0.5% O2 hypoxic conditions for 48 hours prior to changing the media to SILAC Flex 
DMEM supplemented with 398.1 μM 15N4-Arginine, which was then incubated for an 
additional 24 hours in hypoxia. Similarly, cells were cultured in complete DMEM for 24 
hours before being switched to 1% FBS and 4mM 15N2-Glutamine and 1mM Glucose for 
3 hours or 10mM U-13C6-Glucose and 4mM glutamine for 24 hours.  
The cells were extracted and analyzed as previously described (Nissim et al., 
1999; Nissim et al., 2011). Briefly, cells were washed twice with ice-cold PBS and then 
scraped in 4% perchloric acid (PCA) on ice, which was then freeze-thawed for three 
cycles. Cell extracts were collected and neutralized using 5 M KOH. The neutralized 
PCA extract was used for measurement of 15N enrichment in arginine, urea, ornithine 
and citrulline. The production of 15N-labeled urea (M+2, containing two 15N), or proline 
from [U-15N] arginine was measured using GC-MS, after separation from neutralized 
PCA extract with an AG-50 column and TBDMS derivatization, as in (Nissim et al., 1999; 
Nissim et al., 2011). Measurement of labelled products was performed using LC/MS 
(Agilent LC 1260 Infinity and Agilent 6410 Triple-Quad MS). Samples prepared from 
neutralized PCA extracts and derivatized with ethylchloroformate.   For measurement of 
15N enrichment we used the MRM, ion-pair links 275-70 and 279-70 for arginine; 276-70 




Measurement of pyridoxal, pyridoxal phosphate, pyridoxine and pyridoxamine 
levels was done using LC/MS, using Poroshell 120EC-C18 column (Agilent).  The MRM 
used were: 248-150 for pyridoxal phosphate; 168-150 for pyridoxal; 170-152 for 
pyridoxine; and 169-152 for pyridoxamine. All preparations and measurements were 
performed in the dark due to light sensitivity. 
Cell Cycle Analysis 
Cells were plated in 10 cm plates until ~60% confluency. To block cells in G1 
phase, cells were treated with 20 µM lovastatin (Abcam) for 24 hours and harvested for 
analysis. To block cells in early S phase, a double thymidine block was performed by 
adding 200 µl of 100 mM thymidine (Sigma-Aldrich) to the media for overnight treatment. 
Cells were released from thymidine block by aspirating media, washing the cells and 
changing media into media containing 25 µM deoxycytidine (Sigma-Aldrich) for 8 hours. 
Media was changed back to thymidine containing media and incubated overnight, before 
cells were harvested for analysis. To synchronize cells in G2 phase and mitosis, 
following a double thymidine block, cells were first released as before for 2 hours. For 
G2-block, RO3306 (Sigma-Aldrich) was added to the cells (10 µM) for 10 hours. For 
mitosis block, nocodazole (0.1 µg/ml) (Sigma-Aldrich) was added for 10 hours. Mitotic 
cells were then collected by mechanical shake off.  
The position of synchronized cells was confirmed by propidium iodide (PI) 
staining. Cells were collected in 15 ml conical tubes and centrifuged at 400 xg for 5 min. 
Supernatant was discarded, washed with 5 ml PBS, and centrifuged at 400 xg for 5 min. 
Supernatant was discarded and cells were re-suspended in 500 µl cold PBS. 100% 
ethanol (5 ml) was added drop wise while gently vortexing to fix the cells and kept 
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overnight at -20 °C. Cells were spun down at 400 xg for 5 min and supernatant was 
discarded. Cells were washed with cold PBS and spun down at 400 xg for 5 min. Cells 
were re-suspended in 500 µl PI staining solution (PBS + 50 µg/ml PI (Sigma-Aldrich) + 
100 µg/ml RNAse A (QIAGEN)), filtered using a 40 µM filter (BD Biosciences), and 
incubated on ice in the dark for 20 min. Samples were run on a BD FACS Calibur (BD 
Biosciences) and analyzed using FlowJo.  
Click-iT™ Plus EdU Alexa Fluor™ 488 Flow Cytometry Assay 
 Cells were incubated with EdU (5-ethynyl-2’-deoxyuridine) for 24 hours and 
harvested following the kit protocol. Briefly, cells were trypsinized, spun down, fixed with 
4% paraformaldehyde, washed with PBS, and incubated with the dye in a saponin based 
buffer for 30 min in the dark. This was followed by flow cytometry on BD FACS Calibur 
and analyses on FlowJo. 
Proteome Profiler Human Angiogenesis Array 
 Xenograft tumors were lysed in PBS containing protease inhibitors and 
processed according to the kit protocol. The lysates were incubated with a series of 
buffered protein base solutions on a rocking platform, before being incubated with the 
antibody cocktail and left overnight. The next day, membranes were washed, incubated 
with HRP-Streptavidin containing buffer, and x-ray exposure was carried out using 
chemiluminescent agents. ImageJ software was used to analyze the intensities of the 
dot blot generated from the array and a heatmap was plotted using GraphPad Prism. 
QUANTIFICATION AND STATISTICAL ANALYSIS  
All statistical analyses were conducted using GraphPad Prism 7.0. All error bars 
represent mean ± S.E.M. One-way ANOVA with Tukey’s multiple comparisons test was 
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used unless otherwise specified. Significance was defined as *p < 0.05, **p < 0.01, ***p 
< 0.001. 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
ARG2 Santa Cruz sc20151 
b-actin Santa Cruz sc47778 
mTOR  Santa Cruz sc1549 
ASS1 Abcam ab124465 
ASS1 Santa Cruz s c-99178 
ASL Sigma-Aldrich HPA016646 
ODC1 Abcam ab126590 
OAZ1 Abcam ab85221 
CD31 Abcam ab28364 
Ki67 BD Biosciences #550609 
LAMP BD Biosciences #555803 
phospho-p70 S6 Kinase (Thr389) Cell Signaling  #9234 
p70 S6 Kinase Cell Signaling #2708 
b-Tubulin Cell Signaling #2146 
phospho-4E-BP1 (Ser65) Cell Signaling #9451 
phospho-histone H3 Cell Signaling #3475S 
4E-BP1  Cell Signaling #9452 
phospho-Akt (Thr308) Cell Signaling #13038 
Akt  Cell Signaling #9272 
p21 Cell Signaling # 2947S 
cleaved caspase 3 Cell Signaling # 9661S 
phospho-Tuberin/TSC2 (Ser939) Cell Signaling #3615 
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tuberin/TSC2 Cell Signaling #3612 
EAAT1  Cell Signaling #5684 
RagB Cell Signaling #8150 
HSP90 Cell Signaling #4874S 
anti-rabbit IgG HRP-linked Cell Signaling #7074 
anti-mouse IgG HRP-linked Cell Signaling #7076 
IRDye 800CW conjugated anti-rabbit Li-COR Biosciences #926-32211 
IRDye 800CW conjugated anti-mouse Li-COR Biosciences #926-32210 
AlexaFluor 680 conjugated anti-rabbit Life Technologies #A21109 
AlexaFluor 680 conjugated anti-mouse Life Technologies #A21058 
Chemicals, Peptides, and Recombinant Proteins 
DMEM Life Technologies 11965-084 
Pen/Strep Life Technologies 15140-122 
HK-2 Keratinocyte SFM Media Life Technologies 10724-011 
SILAC Flex DMEM Life Technologies A24939-01 
DMEM for Silac  Life Technologies 88364  
Glucose-free DMEM Life Technologies 11966-025 
Glutamine Life Technologies 25030-081 
Accutase Life Technologies A1110501 
Standard FBS Gemini 900-108 
Dialyzed FBS Gemini 100-108 
U-13C6-Glucose Cambridge Isotopes CLM-1396 
15N2-Glutamine Cambridge Isotopes NLM-1328 
15N4-Arginine Cambridge Isotopes  NLM-396-PK 
Glucose Sigma Aldrich G8270 
Putrescine Sigma Aldrich P5780 
Spermidine Sigma Aldrich S0266 
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Spermine Sigma Aldrich S4264 
Ornithine Sigma Aldrich O6503 
Aspartate Sigma Aldrich A7219 
Lysine Sigma Aldrich L5501 
Arginine Sigma Aldrich A8094 
Phenol Red Sigma Aldrich P0290 
WST-1 Sigma Aldrich 5015944001 
Adenosine Sigma Aldrich A4036 
Guanosine Sigma Aldrich G6264 
Thymidine Sigma Aldrich T1895 
Cytidine Sigma Aldrich C4654 
Enhanced chemiluminescent substrate Perkin Elmer NEL105001EA 
Matrigel matrix Corning 354234 
BioServ Dox Diet (200mg/kg) Fisher Scientific S3888 
Critical Commercial Assays 
RNeasy Mini kit Qiagen #74104 
High Capacity RNA-to-cDNA kit Applied Biosystems #4368814 
Arginase Activity Assay kit Abnova KA1609 
Urea Colorimetric Assay kit Biovision K375-100 
QuikChange II mutagenesis kit Agilent #200521  
Click-iT™ Plus EdU Alexa Fluor™ 488 Flow 
Cytometry Assay Kit 
Life Technologies C10633 
Proteome Profiler Human Angiogenesis 
Array Kit 
R & D Systems ARY007 
Experimental Models: Cell Lines 
HK-2 ATCC CRL-2190 
769-P ATCC CRL-1933 
786-0 ATCC CRL-1932 
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A498 ATCC HTB-44 
Experimental Models: Organisms/Strains 
Mouse: NIH III nude, female homozygous Charles River #201 
Oligonucleotides   





This paper N/A 





This paper N/A 





This paper N/A 
ACTB Life Technologies HS01060665_G
1 
18S Life Technologies HS03928985_G
1 
ASS1 Life Technologies HS01597989_G
1 
ARG2 Life Technologies HS00982833_M
1 
ASL Life Technologies Hs00902699_M
1 
Recombinant DNA   
pLKO.1 Scramble Addgene 17920 





pLJM1-Flag-RagBGTP-Q99L Addgene 19315 
pCDNA3-FLAG-MTOR-R2505P    Addgene 69015 
pCDNA3-FLAG-MTOR-L1460P Addgene 69006 
LentiCRISPR v2 Addgene 52961 
ARG2 SH-1 GE Dharmacon TRCN00000510
18 
ARG2 SH-2 GE Dharmacon TRCN00000510
20 
ASS1 SH-3 GE Dharmacon TRCN00000455
54 
ASS1 SH-4 GE Dharmacon TRCN00000455
53 
ASL ShRNA GE Dharmacon RHS3979-
201794747 
pCDH-CMV-MCS-EF1-Puromycin System Biosciences CD510B-1 
ARG2 cDNA System Biosciences MHS6278-
202800846 
ASS1 cDNA System Biosciences MHS1010-
202694229 
OAZ1 cDNA System Biosciences MHS6278-
202858287 
PDXK cDNA System Biosciences MHS6278-
202827839 
ASL cDNA System Biosciences MHS6278-
202755499 
Software and Algorithms   









CHAPTER 3: RESULTS 
 
ccRCC Distinguished by Loss of Urea Cycle Enzymes 
We employed metabolic gene set and direct metabolomic analyses of 
matched human ccRCC tumor and adjacent healthy kidney samples to identify 
the most significantly suppressed metabolic pathways in renal cancers (Li et 
al., 2014). These determined that genes encoding multiple urea cycle 
enzymes, including arginase 2 (ARG2), argininosuccinate synthase 1 (ASS1), 
and argininosuccinate lyase (ASL) (Figures 2A and 2B) were, along with those 
encoding carbohydrate storage enzymes (Li et al., 2014), the most significantly 
downregulated in ccRCC. Data from The Cancer Genome Atlas (TCGA) also 
revealed ARG2 and ASS1 copy number loss in 38% and 24% of ccRCC 
patients, respectively, and copy number gain of ASL in 40% (Figure 2C). Of 
note, ARG2 copy number loss is accompanied by ASS1 deletion in 
approximately 40% of ARG2-deficient ccRCCs (n=184), and ARG2 and ASS1 
mRNA expression in multiple cohorts was lower in ccRCC tumors compared to 
normal kidney, irrespective of disease stage (Figures 2D, 3A, and 3B). 
Importantly, combined ARG2 and ASS1 loss in ccRCC tumors correlated with 
a nearly three-year reduction in patient survival, compared to patients whose 
tumors retained wild type ARG2 and ASS1 copy number (Figure 3E). These 
differences are reflected in markedly reduced ARG2 and ASS1 protein 
abundance in ccRCC tumors as assessed by immunohistochemistry (IHC) 
staining of primary ccRCC tissue (Figure 2F, and 3C) and primary sample 
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cores (Figure 3D). Loss of ARG2 and ASS1 could reflect a less “differentiated” 
phenotype or reentry into the cell cycle by ccRCC cells. We assessed ARG2 
and ASS1 expression in HK-2 cells arrested at different cell cycle stages using 
pharmacological approaches (Figure 3E-F). However, ARG2 and ASS1 mRNA 
levels were actually elevated in G1/S phases, relative to G2 and M. ARG2 and 
ASS1 protein levels were similarly increased during S phase (Figure 3F). 
These data indicate that ARG2 and ASS1 expression is not downregulated 
during proliferation, suggesting that their under expression in ccRCC is not a 
consequence of cellular dedifferentiation The abundance of multiple 
metabolites in the “urea cycle, arginine, and proline metabolism” KEGG 
classification was also significantly altered, as arginine, proline, and urea levels 
were all lower in ccRCC tumors compared to the normal kidney (Figure 2G). In 
particular, the nitric oxide synthase inhibitor dimethylarginine was reduced in 
ccRCC tumors, which may contribute to robust vascularization characteristic of 
ccRCC (Aziz et al., 1994; De Gennaro Colonna et al., 2009). Given the high 
frequency of gene copy number loss, reduced mRNA and protein expression, 
altered urea cycle metabolite levels, and correlative survival differences, we 
further explored the role of ARG2 and ASS1 as potential metabolic 




Figure 2. Urea Cycle mRNA, Protein, and Metabolite Alterations in ccRCC 
A. Metabolic gene set analysis of RNAseq data provided by the TCGA, classified 
according to KEGG (Li et al., 2014). Generated metabolic gene sets were ranked based 
on their median fold expression changes in ccRCC tumor (n=480) vs. normal tissue 
(n=69) and plotted as median ± median absolute deviation. 
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B. The complete urea cycle as configured in the liver. Inset: TCGA-derived gene 
expression changes of urea cycle enzymes in ccRCC. 
C. Copy number variation and mutational burden of urea cycle enzymes in 184 
ccRCC tumors (data from TCGA). 
D. ARG2 and ASS1 mRNA levels in ccRCC (TCGA). ***p <0.001, Welch’s t-test. 
E. Copy number variation in ARG2 and ASS1 in ccRCC patients. Kaplan-Meier 
survival 
analysis of copy number loss in ARG2 and ASS1 (from TCGA data). Mantel-Cox log-
rank test was performed. 
F. Representative immunohistochemistry images of ARG2 or ASS1 protein in 
primary ccRCC, N = normal, T = tumor. Scale bars represent 100 µm 
G. Violin plot of urea cycle metabolite abundance in primary ccRCC combining two 
independent datasets, n = 158 (Hakimi et al., 2016; Li et al., 2014). Data are displayed 
as the log2 tumor/normal fold change and are pseudo-colored according to the intensity 
of the fold change in median. The internal bars represent the mean and SD of 158 
tumor/normal pairs. 
Abbreviations: ARG2, arginase 2; ASS1, argininosuccinate synthase 1; ORNT1, 
ornithine translocase 1 (also called SLC25A15); CPS1, carbamoylphosphate synthase 1; 




Figure 3. Urea Cycle mRNA, Protein, and Metabolite Alterations in ccRCC 
A. ARG2 and ASS1 mRNA levels in ccRCC segregated by disease stage (TCGA). 
B. qRT-PCRanalysis of primary matched normal kidney and ccRCCs (obtained from 
the Collaborative Human Tissue Network as an independent cohort) also demonstrate 
reduced ARG2 and ASS1 expression in tumors relative to health kidney cortex. 
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C. Additional immunohistochemistry images of ARG2 or ASS1 protein in primary 
ccRCC, N = normal, T = tumor. Scale bars represent 200 µm. 
D. Immunohistochemistry staining on primary ccRCC tissue microarrays (US 
Biomax) and quantification of staining intensity. N = normal, T = tumor. 
E. Flow cytometry plots of HK-2 cells arrested at various cell cycle phases using the 
indicated drug treatments. 
F. ARG2 and ASS1 mRNA and protein abundance in HK-2 cells across various cell 
cycle phases; data normalized to an asynchronous population of cells (A). Error bars 
represent SEM of 3 replicates. 
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ARG2 and ASS1 Re-expression suppress ccRCC cell growth 
 
To assess the functional consequences of decreased ARG2 and ASS1 
expression in ccRCC, we compared control HK-2 immortalized proximal tubule 
kidney epithelial cells, which retain ARG2 and ASS1, to several ccRCC cell 
lines that lack detectable ARG2 and/or ASS1 protein (Figure 4A). Whereas all 
ccRCC cell lines lack significant ARG2 expression (consistent with primary 
patient samples), only a subset (786-O, A498, RCC10, UOK101) exhibit 
decreased ASS1 abundance when cultured in vitro, and 786-O and A498 cells 
were consequently chosen for the majority of subsequent analyses. Stable 
knockdown of ARG2, ASS1, or both ARG2 and ASS1 (Double KD), mRNAs 
(Figure 4B) increased proliferation of control HK-2 cells in tissue culture (2D 
growth; Figure 4C) and anchorage-independent 3D soft agar growth assays 
(Figure 4D); moreover, the 3D growth effects were enhanced when both ARG2 
and ASS1 were reduced simultaneously. HK-2 cells were grown in low 
serum/low glucose conditions (1% FBS, 1 mM glucose) to mimic nutrient 
availability typical of the tumor microenvironment. These results were 
subsequently confirmed using clonally selected HK-2 cells with CRISPR/Cas9 
mediated deletion of ARG2 or ASS1 (Figure 4E). Remarkably, loss of a single 
urea cycle enzyme (i.e. ARG2 or ASS1) was sufficient to give normal kidney 
cells a significant growth advantage. Conversely, ectopic ARG2 and/or ASS1 
re-expression in polyclonal 786-O and A498 ccRCC cells reduced 3D spheroid 
volume, the number of cells per spheroid, soft agar colony formation, and 2D 
growth (Figures 6A-B, and 5A). Interestingly, ARG2 re-expression only 
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modestly inhibited the growth of UMRC2 ccRCC cells (Figure 5B), which may 
reflect the presence of endogenous ASS1 and slightly elevated baseline ARG2 
in these cells, compared to other ccRCC cell lines (Figure 4A). Of note, ARG2 
and ASS1 re-expression was carefully titrated in an attempt to match protein 




Figure 4. Loss of ARG2 and ASS1 Enhances Proliferation of Normal 
Kidney Cells 
A. ARG2 and ASS1 protein levels in HK-2 kidney epithelial and various 
ccRCC cell lines. Tubulin or actin served as loading controls. 
B. Upper panel: short hairpin-mediated knockdown of ARG2, ASS1, or 
both 
simultaneously (Double KD) in HK-2 cells. Tubulin or actin served as loading 
controls. Lower panel: mRNA levels after knockdown with two independent 
56 
 
hairpins. Error bars represent SEM of 3 independent replicates. 
C-D. Knockdown of ARG2 or ASS1 augments HK-2 cell growth in (C) 2D 
growth and (D) 3D soft agar colony formation assays. Double KD experiments 
employed ARG2 SH-1 and ASS1 SH- 4. In (C), cells were grown in 1% FBS 
and 1 mM glucose media (changed every 2 days). Error bars represent SEM 
from 3 replicate wells. **p < 0.01, ***p < 0.001, one-way ANOVA with Tukey’s 
multiple comparisons test. 
E. Clonally selected CRISPR/Cas9-mediated ARG2-/- or ASS1-/- HK-2 cells 
demonstrate enhanced growth. Guide RNA against EGFP was used as a 
control, ns = non-specific band. Cells were grown in 1% FBS and 1 mM 






Figure 5. ARG2 Suppresses ccRCC Growth in vitro 
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A. Left panel: Ectopic expression of ARG2 and/or ASS1 in A498 ccRCC cells. 
Numbers below ARG2 and ASS1 western blots represent quantified fold change in 
protein compared to normal HK-2 cells. Right panel: A498 growth assay in complete 
media. Error bars represent SEM of 3 replicates. 
B. Left panel: Ectopic expression of ARG2 in UMRC2 ccRCC cells. Right panel: 3D 
soft agar colony forming assay of UMRC2 cells. Error bar represents SEM of 3 
replicates, Welch’s t-test. 
C. 786-O, A498, and HK-2 cell growth assay in complete versus arginine deficient 
media. 
D. 786-O and HK-2 growth assays in complete versus arginine depleted conditions 
(50-fold decrease compared to normal culture conditions). 
E. Ectopic expression of wild type ARG2 and ARG2 H160F mutant protein in 786-O 
cells. Densitometry analysis of Li-COR captured images indicate that ARG2 mutant 
protein is expressed at 75% of wild type ARG2 protein. Lane 4 has half the amount of 
wild type ARG2 protein loaded for reference. *p < 0.05, **p < 0.01, ***p < 0.001, a one-
way ANOVA with Tukey’s multiple comparisons test was conducted for each dataset 
unless otherwise specified. 
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ARG2 Suppresses ccRCC Growth via its Enzymatic Activity 
 
To confirm that exogenously expressed ARG2 and ASS1 proteins are 
catalytically active, we performed liquid chromatography-mass spectrometry 
(LC/MS) to measure arginine, citrulline, and aspartate levels in transduced 
786-O ccRCC cells. As expected, arginine levels were significantly reduced 
upon ARG2 expression, as were both citrulline and aspartate upon ASS1 
expression (Figure 6C). Combined ARG2 and ASS1 expression decreased 
the abundance of all three urea cycle metabolites, most notably citrulline and 
aspartate. We reported previously that a key metabolic enzyme, FBP1, has 
catalytic activity-independent mechanisms of tumor suppression in ccRCC (Li 
et al., 2014). To test whether this was true for ARG2, we generated a 
missense mutation (ARG2 H160F) that abolished enzymatic activity (Figure 
6D), consistent with previous reports (Xiong et al., 2014). In a 3D spheroid 
growth assay, expression of wild type ARG2 dramatically reduced ccRCC 
spheroid volume and the number of cells per spheroid, whereas ARG2 
H160F failed to suppress spheroid growth (Figure 6E) and soft agar colony 
formation (Figure 6F). These data clearly demonstrate that ARG2 catalytic 
activity is required for ccRCC growth suppression, in contrast to FBP1 (Li et 
al., 2014). Loss of multiple urea cycle enzymes would be predicted to render 
ccRCC cells dependent on exogenous arginine for proliferation. Indeed, 786-
O and A498 cells appear to be arginine auxotrophs, based on the absence of 
growth in arginine deficient media (Figure 5C). These findings are consistent 
with Yoon et al., who previously reported that kidney cancer cells exhibit low 
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ASS1 levels and sensitivity to arginine deprivation (Yoon et al., 2007). 
However, unlike hepatocytes, normal kidney cells do not express all urea 
cycle enzymes (see Figure 7C). Therefore, they would not be expected to 
survive total deprivation of exogenous arginine either (Figure 5C). ccRCC 
cells suggesting that they may be less sensitive to arginine depletion, as 




Figure 6. ARG2 Enzymatic Activity is Required for ccRCC Growth 
Suppression 
A. Left panel: Ectopic expression of ARG2 and/or ASS1 in 786-O ccRCC 
polyclonal populations. Numbers below ARG2 and ASS1 western images 
represent the quantified fold change in protein compared to normal HK-2 
cells. Right panel: 3D spheroid growth assay of 786-O cells. After three 
weeks of growth, spheroid volume was measured via microscopy and the 
number of cells per spheroid was counted after accutase digestion of 
spheroids to a single cell suspension. Error bars represent SEM of three 
independent replicates containing 12 spheroids each. 
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B. Soft agar growth assays of 786-O ccRCC cells. Error bars represent 
SEM of 5 replicate wells. 
C. LC/MS quantitation of arginine, citrulline, and aspartate in 786-O cells 
stably expressing urea cycle enzymes. Error bars represent SEM of 4 
replicates. 
D. Expression and activity of wild type (WT) and H160F mutant ARG2 
and 
E. 786-O spheroid growth assay demonstrating ARG2 catalytic activity-
dependent growth suppression. Error bars represent SEM of 3 independent 
replicates containing 12 spheroids each. 
F. 786-O soft agar colony growth assay depicting ARG2 catalytic activity-
dependent growth suppression. Error bars represent SEM of 3 replicate wells. 
*p < 0.05, **p < 0.01, ***p < 0.001, a one-way ANOVA with Tukey’s multiple 
comparisons test was conducted for each dataset unless otherwise specified. 
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Figure 7. ARG2 Suppresses ccRCC Growth in vivo 
A. 786-O xenograft tumor weight (of tumors shown in Figure 4A). At the 
end of each assay, mice were sacrificed and, tumors dissected and weighed. 
B. ARG2 activity in xenograft tumors was confirmed by measuring urea 
concentration. Urea was measured in four pairs of matched control and urea 
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cycle enzyme-expressing ccRCC tumors. *p 
< 0.05, **p < 0.01, ***p < 0.001, Welch’s t-test. 
C. Schematic representation of the “urea shunt” in renal epithelial cells. 
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ARG and/or ASS1 suppress ccRCC growth in vivo, independent of mTORC1 
activity and nucleotide synthesis 
We evaluated the effects of ARG2 and/or ASS1 expression on ccRCC 
xenograft tumor growth in nude mice, as a fully accurate, autochthonous 
murine ccRCC model has only recently been described (Nargund et al., 2017). 
Ectopic ARG2 expression in 786-O ccRCC xenografts reduced tumor growth in 
vivo, which was further suppressed by co-expression of ARG2 and ASS1 
(Figures 8A and 7A). Compared to ARG2, ASS1 expression produced a 
relatively modest effect on tumor volume at later time points (days 38-40) 
(Figure 8A), although the reduction in tumor mass at the experimental endpoint 
failed to achieve statistical significance (Figure 7A). It is noteworthy that ARG2 
H160F failed to significantly suppress either tumor volume or mass (Figures 
8A, 7A), consistent with in vitro assays described in Figure 6. Interestingly, the 
ASS1-, ARG2-, and ASS1/ARG2-expressing tumor cohorts exhibited 
decreased tumor cell proliferation and some evidence of reduced mTORC1 
activity (Figures 8B-C), and ARG2- and combined ARG2/ASS1- expressing 
tumors displayed the expected patterns of altered urea concentration (Figure 
7B). We then focused primarily on ARG2, as it exhibited the most consistent 
and robust suppression of growth and mTORC1 activity in multiple ccRCC cell 
lines both in vitro and in vivo (e.g. Figures 6A, 8A ,8C, and 7A). Moreover, the 
urea “cycle” is configured somewhat differently in the kidney than the liver, 
where ARG2 resides in the mitochondria rather than the cytoplasm in renal 
cells (compare Figures 2B and 7C), rendering ARG2 mediated reactions 
somewhat biochemically “independent”. An unbiased metabolomics analysis to 
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assess the impact of expressing ARG2 in ccRCC xenograft tumors was 
performed (Figure 8D). ARG2 expression caused striking widespread 
metabolic changes, most notably significant decreases in the concentration of 
multiple amino acid, lipid, nucleotide, and vitamin/cofactor metabolites. In 
particular, ARG2 expression decreased the abundance of 10 naturally 
occurring amino acids (Figure 8E). 
Given the requisite role of amino acids in controlling the activity of the 
mechanistic target of rapamycin (mTOR) nutrient sensing pathway (Gonzalez 
and Hall, 2017), we postulated that ARG2 might suppress ccRCC growth by 
decreasing amino acid abundance and thus, mTORC1 activation. Indeed, 
mTORC1 activity was reduced in xenograft tumors expressing either ARG2, 
ASS1, or both enzymes, as determined by phospho-S6K1, phospho-S6, 
phospho-4E-BP1 and phospho-ULK-1 levels (Figures 8C, 9A, and 9B). The 
phosphorylation status of these mTORC1 substrates was not accompanied by 
changes in the activity of upstream regulators Akt and TSC2 (Figure 9A), which 
respond to growth factors instead. However, several experimental results 
indicated that the ARG2-dependent phenotypes we observed are (at least in 
part) mTORC1- independent. For example, we initially hypothesized that 
elevated citrulline in ASS1-deficient ccRCC cells might activate mTORC1, as 
previously reported (Breuillard et al., 2015; Cynober et al., 2013; Le Plenier et 
al., 2012; Moinard and Cynober, 2007); however, exogenous citrulline (in 
contrast to leucine) had no consistent effect on S6 and 4E-BP1 
phosphorylation in 786-O cells, even when present at supra-physiological 
levels (Figure 9C). 
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An alternative model posited that ARG2 and ASS1 expression could 
alter the subcellular distribution of mTORC1, which responds to amino acid 
stimulation by translocating to the lysosomal surface in a RAG GTPase-
dependent manner (Bar-Peled and Sabatini, 2014). However, expression of 
these enzymes in ccRCC cells had no effect on subcellular mTORC1 
lysosomal localization (Figure 9D). We also introduced two constitutively active 
mTORC1 mutants (R2505P and L1460P; (Grabiner et al., 2014)) into 786-O 
cells with and without ARG2 reconstitution. Figure 9D indicates that both 
constructs override ARG2-mediated mTORC1 suppression, based on 
phospho-S6 levels. Intriguingly, mTORC1 R2505P and L1460P, if anything, 
suppress growth of control cells in soft agar colony formation assays, while 
failing to fully restore the growth of ARG2-expressing cells (Figure 9E). A direct 
comparison is provided when one assesses the vector plus mTORC1 R2505P- 
transduced cells to ARG2 plus mTORC1 R2505P- expressing cells. These 
observations can be explained by suppression of basal autophagy (which may 
be active in 3D growth assays where colonies develop O2/nutrient gradients) 
by constitutively active mTORC1. We also examined whether ARG2 instead 
modulates mTORC1 through global changes in amino acid availability, by 
expressing a constitutively active form of RagB, RagB Q99L (RagBGTP), which 
confers high levels of mTORC1 activity (Sancak et al., 2008), even in the 
absence of amino acids (see Figure 9G). We reasoned that if ARG2 
suppresses ccRCC tumor growth by depleting amino acids, thereby reducing 
mTORC1 activity, constitutively active RagBGTP should rescue ARG2-
dependent tumor growth suppression. Unexpectedly, the growth of 786-O 
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ccRCC xenograft tumor cells co-expressing both ARG2 and RagBGTP was 
equivalent to those expressing ARG2 alone, indicating that mTORC1 is not 
solely responsible for ARG2-dependent ccRCC growth suppression (Figure 
9H). 
Decreased expression of ASS1 and ASL has been reported in other 
cancers (Huang et al., 2013; Kobayashi et al., 2010; Rabinovich et al., 2015), 
although ccRCC appear to have suppressed additional urea cycle enzymes, 
especially ARG2. Of note, Rabinovich et al. demonstrated that ASS1 
deficiency increases cytoplasmic aspartate levels (Rabinovich et al., 2015), 
which are critical for maintaining pyrimidine biosynthesis in multiple cancer cell 
lines (Birsoy et al., 2015; Sullivan et al., 2015). Specifically, ASS1-deficient 
sarcoma cells divert aspartate away from the urea cycle to support de novo 
nucleotide production and DNA replication (Rabinovich et al., 2015). Because 
ARG2-expressing xenograft tumors exhibited reduced aspartate levels (Figure 
8E), we explored the possibility that supplying exogenous aspartate might 
reverse ARG2-dependent growth suppression, given that ARG2 re-expression 
also resulted in decreased nucleotide abundance (Figure 8D). We employed 
the 3D spheroid assay for this purpose, where ARG2 re-expression results in 
decreased spheroid volume (Figure 11A and B), mimicking reduced in vivo 
tumor growth (Figure 8A). However, supplementation with supra- physiological 
levels of aspartate (20 mM) was incapable of increasing cell proliferation in 
ARG2 reconstituted 786-O spheroids (Figure 11C). 786-O cells express 
relatively low levels of the glutamate-aspartate transporter SLC1A3, also 
known as the excitatory amino acid transporter, or EAAT1 (data not shown), 
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which could result in poor aspartate transport (Birsoy et al., 2015). We 
therefore generated 786-O cells stably expressing human SLC1A3/hEAAT1 
and cultured them in media containing 150 µM aspartate in a 2D growth assay, 
along with vector controls (Figure 11D). If anything, SLC1A3/hEAAT1 
overexpression resulted in decreased rates of ARG2/786-O cell proliferation 
relative to control cells. To confirm that 786-O cells import aspartate from 
extracellular medium, cells expressing both exogenous ARG2 and the 
aspartate transporter hEAAT1 were cultured with 13C-labelled aspartic acid for 6 
hours and intracellular 13C-aspartate measured using GC/MS. In the results 
shown in Figure 11E, we observed that 786-O cells take up aspartate 
irrespective of ARG2 expression, although exogenous hEAAT1 enhances 
aspartate transport by 30-40X in both settings. Therefore, the results 
presented in Figure 11C and S5D reflect cells importing exogenous aspartate, 
especially when expressing hEEAT1. 
Kim et al. recently determined that increased expression of the urea 
cycle enzyme carbamoyl phosphate-1 in Kras/LKB1 mutant lung cancer cells is 
essential to maintain their intracellular pyrimidine pools, DNA synthesis, and 
genome integrity (Kim et al., 2017). However, culturing ARG2/786-O cells in 
various concentrations of cytidine, thymidine, or all four deoxyribonucleosides 
failed to change 3D spheroid growth rates over a two-week period (Figure 11E-
F). Overall, these results strongly suggest that 1) decreased mTORC1 
signaling, aspartate levels, and/or nucleotide availability are not sufficient to 
fully account for the growth suppressive effects of ARG2 in ccRCC, and 2) 











A. 786-O xenograft tumor growth in nude mice, where cells re-express ASS1, wild 
type ARG2, ARG2 H160F mutant, or both ASS1 and ARG2 (n = 10 mice in each cohort, 
except for n=5 for the ARG2 H160F study). 
B. Immunohistochemistry staining for Ki67 as a marker of proliferation in xenograft 
tumors expressing urea cycle enzymes, high power fields (HPF). ( 
C. mTORC1 activity in ARG2- or ASS1-expressing xenograft tumors, as assessed 
by the mTORC1 targets phospho-S6K1, phospho-S6, and phospho-4E-BP1. 
D. Unbiased metabolomic analysis of control or ARG2 expressing xenograft tumors, 
n = 7 for each cohort. ARG2 expression causes robust global reductions in several 
categories of metabolites, especially lipids, nucleotides, and biosynthetic co-factors. 
E. Amino acid abundance in 786-O xenograft tumors (n = 7). Data are represented 
as the percent change in amino acid, after normalization to each corresponding control 




Figure 9. mTORC1 Not Solely Responsible in ARG2-dependent Growth 
Suppression 
A-B. mTORC1 activity is reduced upon combined ARG2 and ASS1 re-expression in 
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xenograft tumors, as assessed by the mTORC1 targets phospho-S6K1 and phospho-
4E-BP1 (A) and phospho-ULK1 (B). 
C. Citrulline does not activate mTORC1 in ccRCC. 786-O ccRCC were treated with 
5 mM citrulline for the indicated times, after which cells were lysed and assessed for 
mTORC1 activity. Numbers below the phospho-S6 western blot represent levels relative 
to total S6 protein at time 0. Leucine treatment was used as a positive control for 
mTORC1 activation. 
D. 786-O cells with ectopic expression of constitutively active mTORC1 point 
mutants (R2505P and L1460P) override ARG2-mediated suppression of mTORC1 target 
phospho-S6. 
E. Soft agar colony formation assay with 786-O cells expressing vector or ARG2, 
and constitutively active mTORC1 mutants. Error bars represent SEM of 3 replicate 
wells. 
F. Immunofluorescence imaging of mTORC1 (red) and LAMP (green) in 786-O 
cells, indicating no consistent change in mTOR localization at LAMP+ lysosomes upon 
ARG2 and/or ASS1 re- expression. Nuclei, stained with DAPI, appear blue. Scale bar = 
20 µm. Inserts represent 5X magnification of a portion of each panel. 
G. 786-O cells stably expressing either ARG2 or RagBGTP in response to amino 
acid deprivation and re-stimulation. Experiment and exact conditions replicated from 
(Sancak et al., 2008). RagBGTP renders 786-O cells insensitive to amino acid 
deprivation. (H) 786-O xenograft tumor growth in ARG2 or ARG2 + RagBGTP 




ARG2 Suppresses ccRCC Growth via Depletion of the Essential Cofactor 
Pyridoxal Phosphate 
To define alternative mechanisms whereby urea cycle enzymes 
influence ccRCC tumor growth, we focused on the downstream metabolites 
altered by ARG2 activity, which hydrolyzes arginine to generate ornithine and 
urea. Ornithine has multiple biochemical fates and can be converted by 
mitochondrial ornithine aminotransferase (OAT) to glutamate-gamma- 
semialdehyde, a substrate for the synthesis of both glutamate and proline 
(Figure 10A). 15N4- arginine tracing in HK-2 cells revealed that M+1 enrichment 
of both glutamate and proline was abolished upon ARG2 knockout (Figure 10B, 
left panel). Conversely, ectopic ARG2 expression in 786-O ccRCC cells 
dramatically increased 15N4-arginine incorporation into glutamate and proline 
(Figure 10B, right panel), suggesting that ARG2 directly controls the levels of 
downstream ornithine metabolites by increasing substrate availability for OAT. 
Of note, the absolute concentration of glutamate and ornithine did not change 
in these experiments (Figure 13A). 
An alternative metabolic fate for ornithine is decarboxylation by 
ornithine decarboxylase (ODC) to generate the polyamine putrescine (Figure 
10A). Interestingly, both OAT and ODC require the cofactor pyridoxal-5’-
phosphate (PLP) for catalysis. PLP is a vitamin B6 derivative involved in 
approximately 4% (~140) of all known cellular enzymatic reactions (Percudani 
and Peracchi, 2003). Vitamin B6 encompasses six various inter-converted 
forms, including pyridoxine (PN), pyridoxal (PL), pyridoxamine (PM), and their 
phosphorylated versions (Figure 10C); however, only PLP is the bioactive 
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cofactor used in enzymatic reactions (Galluzzi et al., 2013). Phosphorylation of 
the various B6 precursors to generate active PLP requires pyridoxal-5’-
phosphate kinase (PDXK), the expression of which is reduced across all 
stages of ccRCC (Figure 10D). 
As PLP is a cofactor in numerous eenzymatic reactions, we 
hypothesized that small perturbations in PLP levels could have significant cell 
growth effects. Furthermore, because ARG2 supplies the ornithine substrate 
for ODC and OAT (Figure 10A), enhanced reaction rates of these enzymes in 
ARG2-expressing cells might deplete PLP pools. Ectopic ARG2 expression 
significantly reduced the concentration of PLP, as expected, with no effect on 
the precursors PL, PN, etc. in 786-O ccRCC cells (Figure 10E, right panel). 
Conversely, deletion of ARG2 in HK-2 cells produced significantly elevated 
concentrations of PLP (Figure 10E, left panel), demonstrating that ARG2 
activity modulates the pool of available PLP. 
In complementary experiments, we ectopically expressed PDXK to 
increase PLP levels (Figure 10F and 10G), which rescued all ARG2-mediated 
growth defects, including slowed 2D proliferation (data not shown), decreased 
3D soft agar colony numbers (Figure 10H), and reduced colony size (Figure 10I). 
This approach was adopted because PLP is too labile to add to semisolid culture 
media as a supplement (data not shown). To demonstrate that ectopic PDXK 
was having the predicted effects on intracellular levels of pyridoxine pathway 
components, we employed LC/MS for their quantification in ARG2- and PDXK- 
expressing 786-O cells (see Experimental Procedures). Certain pyridoxal 
derivatives (PM, PNP, PMP) were difficult to accurately measure, as they exist 
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at the borderline of detection in our experimental system. Nevertheless, 
expressing PDXK in 786-O cells reduced intracellular levels of the PLP 
precursors PN, PL, and PM (Figures 10G and 13B). Interestingly, steady-state 
PLP levels were also decreased in PDXK-expressing vector control cells 
(Figure 10G), likely due to PLP consumption by multiple intracellular reactions. 
However, ectopic PDXK expression increases PLP levels in ARG2-expressing 
cells, albeit not to the levels observed in controls (Figure 10G). In aggregate, 
these data support the hypothesis that ARG2 inhibits ccRCC growth, at least in 
part, by depleting the intracellular PLP cofactor pool, resulting in reduced 








A. Schematic representation of 15N4-Arginine labeling into glutamate and proline 
synthesis. Ornithine decarboxylase (ODC) and ornithine aminotransferase (OAT) 
reactions and their requirement for pyridoxal phosphate (PLP) as a cofactor are 
highlighted. Closed red circles represent heavy nitrogen (15N) while open black circles 
represent carbon atoms (12C). 
B. ARG2 controls the downstream synthesis of glutamate and proline. HK-2 (left 
panel) or 786-O cells (right panel) incubated with 15N4-Arginine. Synthesis of glutamate 
and proline from arginine results in one -15N incorporation (M1 enrichment), represented 
as atom percent excess (APE). Error bars represent SEM of 3 and 5 replicates for HK-2 
and 786-O, respectively. 
C. Schematic for the synthesis of PLP. Several precursor forms of pyridoxal exist 
and interconverted between their phosphorylated versions; only PLP is the bioactive 
cofactor. 
D. mRNA levels of pyridoxal kinase (PDXK) in ccRCC (data from TCGA). Box plots 
represent 69 normal and 480 tumor samples, one-way ANOVA with Tukey’s multiple 
comparisons test. 
E. ARG2 directly modulates the levels of bioactive PLP. HK-2 (left panel) or 786-O 
cells (right panel) were grown in 1% FBS with 1 mM glucose for 24 hours (HK-2) or 
hypoxia (0.5% O2) for 48 hours (786-O) prior to quantifying the total PL, PLP, PN, and 
PM levels via LC/MS. Error bars represent SEM of 3 and 5 replicates for HK-2 and 786-
O, respectively. 
F. Ectopic ARG2 and/or PDXK expression in 786-O cells. 
G. PDXK overexpression alters levels of pyridoxine pathway components. 786-O 
cells were cultured under hypoxia (0.5% O2) for 48 hours prior to quantifying total PL, 
PLP, PN, and PM levels via LC/MS. Error bars represent SEM of 5 replicates. 
H-I. PDXK expression reverses ARG2-dependent growth suppression. 3D soft agar 
colony formation assay of 786-O cells ectopically expressing either ARG2 and/or PDXK. 
(H) Quantification of colony number and (I) representative pictures of colony size. Scale 
bar represents 25 μm. Error bars represent SEM of 6 replicate wells for each condition, 
one-way ANOVA with Tukey’s multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 
0.001, a two-way ANOVA with Tukey’s multiple comparisons test was conducted for 




Figure 11. Exogenous Aspartate and Nucleosides Have No Effect 
on ARG2 Expressing ccRCC Cells 
A. Matrigel-based 3D spheroid growth assay of 786-O cells. 
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Spheroid volume was measured via microscopy over two weeks. 
B. Representative pictures showing spheroid volume. 
C. Exogenously provided aspartate is detrimental to ARG2 re-
expressing ccRCC cells. A matrigel- based 3D spheroid growth assay 
of 786-O cells was supplemented with 20 mM aspartate. 
D. Overexpression of the human glutamate-aspartate transporter, 
or “excitatory amino acid transporter” (hEAAT1), in 786-O cells in 
media supplemented with exogenous aspartate (Asp) failed to rescue 
ARG2-mediated growth suppression in a 2D growth assay. 786-O cells 
stably expressing ARG2 with and without hEEAT1 cultured in 150 μM 
aspartate (where indicated), and growth assessed with a WST-1 based 
assay. 
E. 13C-labelled aspartate uptake in ccRCC cells. 786-O cells with 
vector or ARG2, and/or hEAAT1 were cultured with 150 M aspartic 
acid for 6 hours and intracellular uptake was measured by GC/MS. SD 
values represent 3 technical replicates. 
F. Exogenously provided pyrimidines do not confer a growth 
advantage upon ARG2 re-expressing 786-O cells. A matrigel-based 3D 
spheroid growth assay was carried out in media supplemented with the 
indicated concentrations of pyrimidines (cytidine and thymidine). 
G. Exogenous nucleosides do not confer a growth advantage on 
ARG2 re-expressing 786-O cells. A matrigel-based 3D spheroid growth 
assay was conducted in media supplemented with 50 μM adenosine, 
guanosine, cytidine or thymidine. Error bars represent SEM of 12 
technical replicates. 
*** p< 0.001, a one-way ANOVA with Tukey’s multiple comparison test. 
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Excess Polyamine Production Upon ARG2 Expression Leads to ccRCC Growth 
Suppression 
We hypothesized that altered polyamine synthesis or metabolism might 
also contribute to the growth suppressive effects of ARG2 expression in 
ccRCC.  Ornithine- derived putrescine is converted to higher order polyamines 
spermidine and spermine through the addition of decarboxy-SAM-derived 
aminopropyl groups (Michael, 2016) (Figure 12A). While polyamines promote 
tumor progression in some contexts (Soda, 2011; Tsujinaka et al., 2011), they 
cause cellular toxicity in other tumor cells (Pegg, 2013), although the precise 
mechanisms by which polyamines either promote or inhibit tumor growth are 
not well characterized. Treatment of 786-O ccRCC cells with exogenous 
putrescine resulted in a dose-dependent toxicity, whereas putrescine had no 
effect on the growth of control HK-2 cells, even at relatively high (10 mM) 
concentrations (Figure 12B). To examine   the sensitivity of non-ccRCC cancer 
cells to exogenous polyamines, we studied prostate cancer cells (VCaP and 
LnCaP), reasoning that the prostate is an important physiological source of 
polyamines. Accordingly, prostate cells were cultured in the presence of 5 mM 
and 10 mM putrescine and appeared to be more resistant to putrescine levels 
toxic for 786-O, even when growing rapidly (Figures 12B and 15B). Putrescine 
concentrations used for these experiments were chosen based on calculations 
described in the Experimental Methods. In aggregate, these data suggest that 
the metabolic wiring of ccRCC cells makes them particularly sensitive to 
changes in polyamine concentrations. 
Hypoxia has been shown to promote the cellular uptake of polyamines 
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in both normal and malignant cells, downstream of HIF1a stabilization (Aziz et 
al., 1994; Babal et al., 2002; Tantini et al., 2006; Tsujinaka et al., 2011). Of 
note, hypoxia can also stimulate ODC expression and activity (Babal et al., 
2002). We speculated that naturally occurring tumor hypoxia and constitutive 
HIF activity might commit ccRCC cells to take up potentially toxic levels of 
polyamines from the microenvironment, thereby selecting for cells with lower 
endogenous polyamine synthesis (Svensson et al., 2008). This hypothesis is 
supported by unbiased metabolomics analyses of two independent ccRCC 
cohorts (n=158 samples in total; (Hakimi et al., 2016; Li et al., 2014) that 
demonstrated a marked overall elevation in putrescine and spermine 
concentrations, with minor elevations in the levels of spermidine (Figure 12C). 
mRNA expression data are also consistent with reduced de novo polyamine 
synthesis in ccRCC cells (Figure 12A). For example, transcripts encoding 
ARG2, ODC1, and spermine synthase (SMS) are expressed at lower levels in 
ccRCC than normal kidney tissue (Figure 12A). Additionally, upstream 
regulators of ODC, which catalzyes the committed step in polyamine synthesis, 
are modulated in a manner consistent with this model. Specifically, ornithine 
decarboxylase antizymes (OAZ) 1, 2, and 3 bind the ODC protein and target it 
for degradation via the 26S proteasome (Tajima et al., 2016). OAZ expression is 
elevated in ccRCC (Figure 12A), consistent with reduced ODC protein levels 
(Figures 6D and S6B). Elevated OAZ expression in ccRCC also correlates with 
worse patient survival (Figure 6E). Furthermore, expression of antizyme 
inhibitor 1 (AZIN1), which regulates polyamine synthesis by binding and 
inhibiting OAZ, thereby stabilizing ODC and promoting polyamine synthesis 
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(Wu et al., 2015), was also reduced in ccRCC samples (Figure 12A), consistent 
with reduced polyamine synthesis. Taken together, these data support the 
hypothesis that altered expression of genes encoding polyamine pathway 
enzymes reduces endogenous polyamine synthesis in ccRCC as an adaptive 
response to the accumulation of toxic polyamines. 
Metabolic tracing experiments were conducted to follow the fate of 15N4-
arginine in ccRCC cells with regard to downstream products such as ornithine 
and putrescine (Figure 14A). Ectopic expression of ARG2 in 786-O ccRCC 
cells led to robust incorporation of 15N4-arginine into M+2 ornithine and urea, as 
well as the downstream metabolite M+2 putrescine (Figure 14B, bottom panel). 
Conversely, 15N4-arginine incorporation into these metabolites was markedly 
reduced in ARG2-deficient HK-2 cells (Figure 14B, top panel). Ectopic ARG2 
expression in 786-O cells elevated arginine-dependent putrescine synthesis 
nearly 3-fold, whereas ARG2 depletion in HK-2 cells reduced this by 
approximately 8-fold, independent of changes in ODC expression. Absolute 
levels of putrescine in 786-O and HK-2 cells were determined to be 2-4 mM 
in media lacking exogenous polyamines (Figure 13A), with ARG2 deletion 
reducing levels by 8X in HK-2 cells, and ARG2 re-expression increasing 
putrescine levels 4X in 786-O cells in these conditions. However, culturing the 
same renal cells in exogenous 2.5 mM putrescine dramatically increased its 
intracellular abundance >10-fold (Figures 14C and 15A). These findings 
indicate that kidney cells actively transport large quantities of polyamines from 
their microenvironment. As expected, both ARG2 expression and/or hypoxia 
increased intracellular putrescine levels (Figure 14C). ARG2 expression also 
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increased the levels of spermidine and spermine, although the magnitude of 
this effect did not attain statistical significance. On the other hand, ARG2 
knockout in HK-2 cells reduced the levels of putrescine (Figure 15A), while 
hypoxia had no effect (15A), likely due to the lack of constitutive HIF activity in 
a VHL wild type setting. 
As stated previously, HK-2 renal epithelial cells gain a proliferative 
advantage when ARG2 expression is reduced or eliminated (Figures 4C-E and 
Figure 14D). To test if reduced polyamine levels contribute to this growth 
advantage, we treated HK-2 cells with exogenous polyamines. CRISPR control 
HK-2 cells were unaffected by exposure to increasing levels of putrescine, 
spermine, or spermidine, (Figures 14D-E and 15B, left panels), while growth of 
ARG2-deficient HK-2 cells was inhibited by putrescine, spermine, and 
spermidine in a dose-dependent manner (Figures 14D-E and 15C, right 
panels). In contrast, exogenous ornithine had no effect on cell growth (Figure 
13C). Stated another way, the growth advantage conferred by ARG2 loss in 
kidney cells is reversed specifically by supplying exogenous polyamines. To 
determine if ODC1 deficiency reverses polyamine overproduction in ARG2-
reconstituted 786-O cells (see Figure 14A), CRISPR/Cas9 was used to 
achieve 70% deficiency in ODC1 protein in 786-O cell pools using ODC1 
sgRNA-3 (Figure 14F). Soft agar colony assays revealed a significant rescue 
of colony formation when ARG2 expression and ODC1 deficiency were 
combined (Figure 14G). These data suggest that ARG2-dependent polyamine 
production, in addition to PLP consumption, directly modulates renal epithelial 
cell growth, where ccRCC cells experiencing tumor hypoxia avoid an 
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overabundance of polyamines (due to uptake) by “rewiring” the biosynthetic 




Figure 12. ccRCC Tumors Exhibit Increased Polyamine Levels and 
Correspondingly Alter Gene Expression to Lower de novo Synthesis 
 A. Schematic representation of polyamine biosynthesis. Each enzyme 
contains a corresponding box plot with TCGA mRNA data in normal (N) and 
ccRCC (T) samples. Each y-axis represents the normalized RNA-seq reads of 
the gene; n = 69 normal kidney and 480 tumor samples. *** p< 0.001 
B. 786-O cells grown under hypoxia (0.5% O2) and supplemented with 
various concentrations of putrescine (Put), and HK-2 cells grown in 1 mM 
glucose, 1% FBS conditions, supplemented with Put. Cell growth was 
assessed by WST-1 assays, and error bars represent SEM from 10 replicate 
wells. Prostate cancer (LnCaP) cells were supplemented with various 
concentrations of putrescine, and cell counts performed over the indicated 
times. Error bars represent SEM from 4 replicate wells. 
C. Polyamine metabolite abundance in primary ccRCC combining two 
independent datasets, n = 158 (Hakimi et al., 2016; Li et al., 2014). Data are 
displayed as the fold change in metabolite abundance of each tumor, 
normalized to its control sample. 
D. Quantification of immunohistochemistry staining of primary ccRCC 
tissue microarray, demonstrating reduced ODC protein in ccRCC tumors. *** p 
<0.001, Welch’s t-test. See image in Figure 13B. 
E. Kaplan-Meier survival analysis of OAZ1 expression (from TCGA data) 
in ccRCC. ‘Low’ versus ‘High’ data are segregated based on the median 
expression of OAZ1. Mantel-Cox log-rank test was performed. Abbreviations: 
OAZ, ornithine decarboxylase antizyme; AZIN1, ornithine decarboxylase 
antizyme inhibitor; ODC1, ornithine decarboxylase1; AMD1, 





Figure13. ARG2 Controls Polyamine Production Which Inhibits Growth 
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A. ARG2 expression results in marked changes in putrescine levels but does not 
affect absolute ornithine or glutamate concentrations. Control or ARG2-/- HK-2 cells 
were grown in 1% FBS and 1 mM glucose for 24 hours (upper panels), whereas control 
or ARG2-expressing 786-O cells were grown under hypoxia (0.5% O2) for 48 hours 
(lower panel), followed by quantification of total ornithine, putrescine, and glutamate 
pools with LC/MS. Error bars represent SEM of 5 replicates. 
B. Steady state concentrations (pmol/ mg protein) of pyridoxal phosphate (PLP) 
precursors upon pyridoxal kinase (PDXK) expression. SD values represent 5 technical 
replicates. 
C. Immunohistochemistry images of primary ccRCC tissue microarrays, N = normal, 
T = tumor (US Biomax); quantification of staining intensity displayed in Figure 10D. 
Welch’s t-test. ***p < 0.001, a two-way ANOVA with Tukey’s multiple comparisons test 





Figure 14. ARG2 Expression Controls Polyamine Concentration and 
Subsequent Growth Modulation 
A. Schematic representation of 15N4-Arginine contribution to polyamine 
biosynthesis. Closed red circles represent heavy nitrogen (15N) while open 
black circles represent carbon atoms (12C). 
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B. ARG2 increases arginine utilization for polyamines. Top panel, HK-2 
cells grown in 1% FBS and 1 mM glucose for 24 hours and then supplemented 
with 15N4-Arginine for an additional 24 hours. M2 enrichment represents the 
proportion of each metabolite containing two - 15N atoms (atom percent excess 
[APE]). Bottom panel, 786-O cells grown under hypoxia (0.5% O2) for 48 hours 
and then supplemented with 15N4-Arginine for an additional 24 hours. Error 
bars represent SEM of 5 replicates. 
C. 786-O cells grown under normoxia or hypoxia (0.5% O2) for 48 hours 
followed by quantification of total polyamine pools with LC/MS. Error bars 
represent SEM of 8 replicates. 
D-E. HK-2 cells grown in 1% FBS and 1 mM glucose and supplemented with 
various concentrations of putrescine or spermine. Error bars represent SEM of 
8 replicates. 
F. CRISPR/Cas9 mediated deletion of ornithine decarboxylase (ODC1) in 
ARG2 reconstituted 786-O cells. Numbers below ODC1 western blot images 
represent the quantified fold change in protein compared to 786-O lines with 
vector or ARG2, respectively. 
G. ODC1 loss in 786-O cells reverses ARG2-mediated growth suppression in a 
soft agar colony formation assay. Error bars represent SEM of 3 replicate 
wells. *p < 0.05, **p < 0.01, ***p < 0.001, a two-way ANOVA with Tukey’s 





Figure 15. ARG2 Effects on Polyamine and Amino Acid Biosynthetic Pathways 
A. Control or ARG2-/- HK-2 cells were grown in 1% FBS and 1 mM glucose for 24 
hours (either normoxia or 0.5% O2) followed by quantification of total polyamine pools 
with LC/MS. Error bars represent SEM of 5 replicates. All media contained 2.5 mM 
putrescine in these assays. 
B. LnCaP cells cultured with indicated concentrations of putrescine. 
C-D. Control or ARG2-/- HK-2 cells were grown in 1% FBS and 1mM glucose and 
supplemented with various concentrations of spermidine or ornithine. Error bars 
represent SEM of 8 replicates. *** p< 0.001, as indicated for Figure 12. 
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Urea Cycle Enzymes ASS1 and ASL Exhibit Diminished Expression in ccRCC 
tumors 
 
We performed metabolic gene set analysis on mRNA expression data 
from the cancer genome atlas (TCGA) with 538 ccRCC tumors and 72 normal 
kidney samples (Li et al.). Based on these analyses, we ascertained that genes 
encoding enzymes of the urea cycle are under- expressed in ccRCC tumors 
when compared to the normal kidney (Figures 16A and 16B). We focused on 
urea cycle enzymes argininosuccinate synthase (ASS1) and argininosuccinate 
lyase (ASL) that convert citrulline and aspartate to arginine and fumarate via 
argininosuccinate. Survival data from TCGA indicated that patients with high 
combined expression of ASS1 and ASL (n=92) did significantly better than 
patients with low combined expression of ASS1 and ASL (n=352) (Figure 16C 
and Figure 17A-B). Furthermore, both ASS1 and ASL are under-expressed in 
ccRCC tumors when compared to the normal kidney tissue (Figure 16D). This 
is also reflected in the lowered protein abundances of ASS1 and ASL in 
matched primary patient tumor-normal cores (Figure 16E and Supp Figure 
17C). Finally, several ccRCC cell lines have decreased ASS1 and ASL when 




Figure 16. ccRCC Tumors Exhibit Alterations in Urea Cycle Components 
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A. Metabolic gene set analysis of mRNA-seq data from The Cancer Genome Atlas 
(TCGA) classified based on KEGG. A ranked list of metabolic gene sets was 
generated based on log2 scale fold expression changes in ccRCC tumors (n=538) 
normal kidney (n=72). 
B. The urea shunt as configured in the kidney. * = Citrulline from diet. 
C. Survival analysis based on TCGA expression data for ASS1 and ASL high (n=90) 
and ASS1 
and ASL low (n= 236) patients. *p< 0.05 
D. mRNA-seq data of ASS1 and ASL in normal kidney versus ccRCC tumors. (TCGA) 
****p< 0.001, ***p = 0.001, Mann-Whitney test. 
E. Representative immunohistochemistry images with quantification for ASS1 or ASL 
protein expression in matched tumor-normal pairs (Biomax KD601) n=50. Scale bars 
represent 100µm. 
****p< 0.001, Welch’s t-test. 
F. ASS1 and ASL protein levels in HK-2 (immortalized kidney epithelial) cells and 




Figure 17. ASS1 and ASL expression affects survival in ccRCC patients 
A. Survival curve based on ASS1 expression in patients from the TCGA. (High n=176, 
low n=352) 
B. Survival curve based on ASL expression in patients from the TCGA (High n=258 low 
n=270) 
C. Log2 scale fold change in ASS1 and ASL protein levels in tumors when compared 
to normal kidney (n=108, Clark et al.) 
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ASL Re-expression Alters Growth in Normal Kidney and ccRCC Cell 
 
In order to recapitulate ASL loss in normal kidney cells we used shRNA 
mediated knockdown ASL in HK-2 cells (Figures 18A and 18B) with two independent 
shRNAs (SH-4, SH- 5), while a scrambled shRNA was used as control. ASL 
knockdown enhanced growth in HK-2 cells in 2D culture (Figure 18C) and a 3D soft 
agar colony formation assay (Figure 18D). Re- expression of ASL alone in 786-O and 
UMRC2 cells modestly suppressed growth in a 3D soft agar colony forming assay 
(Figure 19). Similar results were obtained for ASS1 re-expression in ccRCC (Ochocki 
et al., 2018). With the aim of combined re-expression of ASS1 and ASL, we re- 
expressed ASL in 769-P cells that have substantial ASS1 expression (Figure 18E). 
This in turn significantly suppressed growth in 2D culture (Figure 18F), where cells 
were grown in low serum (1% FBS, standard DMEM) conditions. Furthermore, this 
suppression was reproduced in a 3D Matrigel based spheroid assay and a soft agar 





Figure 18. ASL Expression Alters Growth in Normal Kidney and ccRCC Cells 
A. mRNA expression levels of ASL in HK-2 cells post knockdown with two independent 
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shRNAs. Scrambled shRNA was used as a control. 
B. Protein levels of ASL in HK-2 cells after shRNA knockdown. Actin is the loading 
control. 
C. and D. ASL knockdown enhances HK-2 cell growth in (C) 2D and (D) 3D soft agar 
colony forming assay. In C, cells were grown in 1% FBS and standard DMEM. Error 
bars represent SEM from three replicate wells. **p< 0.01, *p< 0.05 
E. Ectopic expression of ASL in 769-P ccRCC polyclonal populations. HK-2 cells used 
as physiologic control. HSP90 and Actin serve as loading controls. 
F- H. ASL re-expression in 769-P cells suppresses growth in (F) 2D, (G) 3D Matrigel 
spheroids, and (H) 3D soft agar colony forming assay. 769-P cells expressing empty 
vector were used as a control. In F, cells were grown in 1% FBS and standard DMEM. 





Figure 19. ASL Expression Suppresses Growth in a ccRCC cells 
A. Ectopic expression of ASL in 786-O polyclonal population. Actin is used as the 
loading control. 
B. 3D soft agar colony forming assay with 786-O cells expressing empty vector control 
and ASL cDNA. **p< 0.01 
C. Ectopic expression of ASL in UMRC2 polyclonal population. Actin is used as the 
loading control. 
D. 3D soft agar colony forming assay with UMRC2 cells expressing empty vector 
control and ASL cDNA. **p< 0.01 
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Combined Re-expression of ASS1 and ASL Suppresses Growth and Alters 
Aspartate Metabolism in ccRCC Cells 
769-P have a number of limitations, chief among them is their inability to form 
in vivo xenograft tumors. In order to explore ASS1 and ASL mediated growth 
suppression in an in vivo setting, we re-expressed ASS1 and ASL in 786-O cells 
(Figure 20A). This re-expression suppresses growth in a 2D growth assay (1% FBS, 
DMEM) (Figure 20B), and a soft agar colony forming assay (Figure 20C). To further 
elucidate the effects of combined re-expression of ASS1 and ASL in 786-O cells, we 
measured steady-state levels of intracellular amino acids (Figure 20D). The combined 
re-expression alters amino acid levels, specifically it depletes cellular aspartate and 
glutamine levels. Aspartate is vital to cellular growth and lowered aspartate levels can 
have detrimental effects on cell growth, affecting pyrimidine production among other 
things. (Sullivan et al., 2015, Birsoy et al., 2015 Rabinovich et al., 2015). The cells try 
to make up for the deficit in intracellular aspartate by making more aspartate from 
glucose and glutamine (Figure 20E and F). This puts an additional metabolic burden 
on the cells and slows down proliferation, specifically DNA production as evidenced by 
an Edu incorporation assay (Figure 20G). ASL re-expression in 769-P cells also 
showed similar trends in intracellular aspartate and glutamine levels (Figure 21A). 
Additionally, 769-P cells expressing ASL exhibit a peculiar sub-G0 peak (Figure 21B) 
in cell cycle experiments hinting at a glitch in pyrimidine synthesis and DNA replication. 
Furthermore, addition of exogenous pyrimidines to the culture medium rescues growth 







Figure 20. Combined Expression of ASS1 and ASL in ccRCC cells Suppresses 
Growth and Alters the Metabolic Landscape 
A. Combined ectopic expression of ASS1 and ASL in 786-O polyclonal population. 
HSP90 serves as the loading control, while HK-2 cells and the normal kidney are 
normal controls. 
B. ASS1+ ASL expression suppresses growth in 786-O cells in a 2D growth assay. 
Error bars represent SEM of 7 wells, cells were grown in 1% FBS in complete DMEM. 
***p< 0.001 
C. 3D soft agar colony forming assay with 786-O cells expressing empty vector control 
and ASS1+ ASL cDNA. Error bars represent SEM of 3 wells. *p< 0.05 
D. Steady-state amino acid in 786-O cells expressing empty vector and ASS1+ASL 
cDNA. Error bars represent SEM of 3 technical replicates. **p< 0.01 
E. Schematic representation of 15N2-Glutamine labeling into aspartate, orotate, and 
argininosuccinate. Argininosuccinate synthase (ASS1), Carbamoyl-phosphate 
synthetase 2, aspartate transcarbamylase and dihydroorotase (CAD enzyme 
complex). The filled in squares represent heavy nitrogen (15N) while clear circles 
represent carbon atoms (12C). 
F. Schematic representation of 13C6-Glucose labeling into aspartate. The filled in circles 
represent heavy carbon atoms (13C). 
G. EdU incorporation assay with 786-O cells expressing empty vector and ASS1+ASL 




Figure 21. ASL Expression in 769-P cells Alters Amino Acid Pools and Affects 
DNA Replication 
A. Steady-state amino acid in 769-P cells expressing empty vector and ASL cDNA. 
Error bars represent SEM of 3 technical replicates. ****p< 0.001, ***p< 0.001 
B. Representative images of cell cycle analyses of 769-P cells indicating a sub-G0 
peak in cells expressing ASL cells at 0 hours and 24 hours. 
C. Exogenously provided pyrimidines (cytidine + thymidine) partially rescue growth in 
769-P cells expressing ASL. Error bars represent SEM of 7 wells. *p< 0.05, ***p< 0.001. 
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Combined Re-expression of ASS1 and ASL Suppresses ccRCC Growth in vivo 
 
There is a strong selective pressure against ccRCC cells with combined re-
expression of ASS1 and ASL and maintaining physiological levels of expression has 
not been trivial (data not shown). To overcome this, we resorted to a doxycycline 
inducible system of expression (Figure 22A). Sustained, combined re-expression of 
ASS1 and ASL, under doxycycline control, significantly suppressed growth in a 
subcutaneous xenograft model, where the mice were fed chow with doxycycline 
(200mg/kg) (Figure 22B). These xenografts exhibit lowered but not significant 
phosphorylated histone H3 (pH3) levels (Figure 22C), significantly enhanced cleaved 
caspase 3 (CC3) (Figure 22D) and p21 staining (Figure 22E). These 
immunohistochemical analyses point to slower proliferation, increased apoptosis and 
defects in cell cycle. It is conceivable that aspartate availability is further limited in a 
harsher in vivo setting, augmenting the growth suppression observed in vitro. 
Interestingly, 786-O cells with ASL re-expression alone (Figure 19A), exhibit modest 
growth suppression in vivo (Figure 23A). Although, this suppression is limited to tumor 
volumes. Moreover, immunohistochemical analyses for pH3, CC3, and p21 were not 
significantly different (Figure 23B-D). 786-O xenograft tumors with just ASL re- 
expression, however, have significantly decreased levels of CD31(Figure 23E), a 
protein staining blood vessels, indicating changes in tumor vasculature. We assessed 
levels of various angiogenic proteins in these tumors using a membrane-based 
sandwich immunoassay (Figure 23F). ASL re- expression in 786-O xenograft tumors 
broadly alters levels of angiogenic proteins. The exact mechanism of these changes in 
unknown but can be associated with nitric oxide synthesis and catalytic activity 
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Figure 22. Combined Re-expression of ASS1 and ASL suppresses growth in vivo 
A. Combined doxycycline induced ectopic expression of ASS1+ ASL in 786-O cells. 
HSP90 is used as a loading control. 
B. 786-O subcutaneous xenograft tumor growth in nude mice, where cells have 
doxycycline induced expression of ASS1 and ASL or empty vector. (n = 6) 
C. Immunohistochemistry staining and quantification for phosphorylated histone H3 as 
marker for proliferation in xenograft tumors. Scale bars are at 100µm. 
D. Immunohistochemistry staining and quantification for cleaved caspase 3 as marker 
for apoptosis in xenograft tumors. Scale bars are at 100µm. **p< 0.01. 
E. Immunohistochemistry staining and quantification for p21 as marker for 







Figure 23. Re-expression of ASL Alone in 786-O Cells Does Not Suppress Growth 
in vivo 
A. 786-O subcutaneous xenograft tumor growth in nude mice, where cells expression 
ASL or empty vector. (n = 5) 
B. Immunohistochemistry staining and quantification for phosphorylated histone H3 as 
marker for proliferation in xenograft tumors. Scale bars are at 100µm. 
C. Immunohistochemistry staining and quantification for cleaved caspase 3 as marker 
for apoptosis in xenograft tumors. Scale bars are at 100µm. 
D. Immunohistochemistry staining and quantification for p21 as marker for 
proliferation in xenograft tumors. Scale bars are at 100µm. 
E. Immunohistochemistry staining and quantification for CD31 as marker for 
vasculature in xenograft tumors. Scale bars are at 100µm. *p< 0.05. 
F. Heat map showing the levels of various angiogenic proteins in 786-O xenograft 




Nearly 40% of ccRCC patients exhibit ARG2 copy number loss, likely reflecting 
ARG2’s position at the nexus of dual mechanisms of tumor inhibition in ccRCC: 1) 
depleting available PLP pools, thereby removing a critical cofactor for multiple essential 
enzymatic reactions, and 2) increasing polyamines to toxic levels. It is now clear that 
altered metabolism plays an important role in cancers of the kidney, an organ 
responsible for excreting excess ammonia (as urea), maintaining inorganic ion 
homeostasis, and generating hormones (e.g. erythropoietin) and glucose. Of note, while 
ASS1 resides on chromosome 9 (9q34.11), ARG2 is located on 14q (14q24.1), a 
chromosome frequently deleted in ccRCC (Shen et al., 2011). Shen et al. previously 
proposed that multiple kidney cancer tumor suppressor genes exist on 14q (in addition 
to HIF1A), and ARG2 represents a very likely candidate. Only 3 out of 448 (0.7%) cases 
reported in the TCGA exhibit a deep deletion at the locus, whereas the remaining 38% 
cases with copy number variation exhibit mono-allelic copy number loss. As ARG2 
mRNA levels are significantly decreased and ARG2 protein expression essentially 
undetectable, we conclude that any retained ARG2 alleles must be silenced in ccRCC 
tumors and cell lines. Interestingly, ASL exhibits copy number gain in ccRCC. We 
attribute this to its location on chromosome 7q (7q11.21), close to a pericentromeric 
region. Regions adjoining the centromere are often duplicated, which may explain the 
higher copy number of ASL detected in ~40% ccRCC. 
 Although gluconeogenesis and glycogen storage represent the most significantly 
down-regulated metabolic pathway in ccRCC, the urea cycle enzymes display a similar 
degree of repression in these tumors. We sought to determine if suppression of the urea 
cycle contributes directly to ccRCC disease progression. Whereas multiple cancers 
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exhibit decreased ASS1 and ASL protein abundance (Huang et al., 2013; Kobayashi et 
al., 2010; Rabinovich et al., 2015), ccRCC appear to have suppressed additional urea 
cycle enzymes, including ARG2. Re-expressing ASS1 (Figure 6) or ASL (Figure 18) in 
ccRCC cells inhibited proliferation, although our data indicate that ARG2 has more 
potent tumor suppressive effects in this setting.  Nevertheless, which urea cycle 
intermediates are critical for these effects remains somewhat open-ended. ASS1-
deficient sarcoma cells depend on aspartate diverted away from the urea cycle to 
support de novo nucleotide production and DNA replication (Rabinovich et al., 2015). 
We observed similar recuse with nucleosides in ASS1+ASL re-expressing cells (Figure 
23), but not in ARG2 re-expressing cells, perhaps hinting at distinct mechanisms of 
suppression. It is also important to contrast our results with those presented in the recent 
report by Kim et al., where Kras/LKB1mutant lung cancers overexpress the urea cycle 
enzyme carbamoyl phosphate-1 to maintain pyrimidine levels and DNA synthesis (Kim 
et al., 2017). ccRCC instead repress the expression of multiple urea cycle enzymes to 
also maintain nucleotide pools by different means, i.e. conservation of a critical 
biosynthetic cofactor (PLP) that ultimately supports their generation. ARG2-expressing 
ccRCC xenografts also exhibited decreased mTORC1 activity, coincident with 
decreased pools of arginine, aspartate, and glycine, suggesting that disrupted amino 
acid homeostasis might result in reduced mTORC1 signaling and cell growth. However, 
high levels of mTORC1 activity conferred by constitutive mTORC1 and RagB activity 
also failed to reverse ARG2-mediated growth suppression. 
 ARG2 expression had significant effects on pyridoxine metabolism, in that its 
deletion in renal epithelial cells, or reconstitution in ccRCC cells, changed overall 
intracellular PLP levels by a surprising 25-35%. Given the significant role of this 
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essential vitamin B6 component in numerous metabolic reactions critical for amino acid 
synthesis, nitrogen homeostasis, and glycogen production, ARG2 loss in ccRCC 
appears to maintain sufficient PLP to support more than 140 biosynthetic reactions that 
contribute to increased biomass and cell division. In fact, changes in PLP pools likely 
account for the substantial disruption of amino acid and subsequent nucleotide 
abundance (due to changes in aspartate levels) observed in ARG2 expressing 
xenografts. In aggregate, pyridoxine metabolism represents an understudied pathway for 
future therapeutic strategies for ccRCC treatment, with pyridoxal kinase a highly 
appealing potential drug target. 
 Metabolic tracing experiments with 15N4-arginine revealed that ARG2 expression 
plays a critical role in arginine conversion to putrescine and urea. Our data indicate that 
human ccRCC tumors accumulate high levels of polyamines, despite having reduced 
ARG2 expression, suggesting that these cells import exogenous polyamines from the 
circulation or tumor microenvironment. The growth advantage conferred to normal renal 
epithelial cells by ARG2 deficiency is reversed by exogenous polyamines, suggesting 
that one benefit of ARG2 deficiency in ccRCC cells is avoiding toxic polyamine 
concentrations by reducing de novo synthesis of putrescine and spermidine. Relatively 
little is known about how polyamines regulate cancer cell behavior, particularly in 
ccRCC, although polyamine biosynthetic enzymes are controlled at the level of 
transcription, translation, and protein degradation by a variety of highly conserved 
feedback loops (see Figure 12A). While intracellular polyamines can support cell division 
and anabolic metabolism (Babal et al., 2002; Svensson et al., 2008; Tsujinaka et al., 
2011), they can also be converted to toxic byproducts like acrolein (Moghe et al., 2015; 
Stevens and Maier, 2008). Preliminary experiments indicate that ARG2-reconstituted 
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ccRCC cells accumulate higher levels of acrolein than control cells (data not shown), 
providing an explanation for why polyamine overabundance results in decreased cell 
vitality. Therefore, further investigation of polyamine influences on renal cancer 
progression is highly warranted. 
 While metabolic adaptations supporting tumor cell growth and division have been 
extensively studied (Palm and Thompson, 2017; Vander Heiden and DeBerardinis, 
2017), global metabolic shifts contributing to tumor cell survival remain less clear 
(Kamphorst et al., 2013; Young et al., 2013). Our findings demonstrate how a single 
metabolic pathway significantly contributes to both processes: PLP conservation 
promotes biomass expansion, while suppression of polyamine synthesis enhances cell 
survival when tumor hypoxia increases polyamine uptake. A third essential process 
underlying disease progression is evasion of the immune system. The overall goal of 
our studies is to identify consistent (if not universal) metabolic differences between 
healthy kidney tissue and ccRCC, a genetically diverse cancer exhibiting significant 
intratumoral genomic heterogeneity. Cancer metabolism research has focused primarily 
on central carbon, amino acid, and lipid pathways, and ccRCC has been previously 
characterized as a metabolic disease with consistent changes in glycolysis, 
gluconeogenesis, and lipid storage. We show here that ammonia metabolism can also 





CHAPTER 4: CONCLUSIONS 
Advances in engineering and computational modeling, along with sophisticated 
clinical processes, have ushered in a renaissance for the field of cancer metabolism. We 
now have an enhanced understanding of complex metabolic phenomena and hope to 
utilize this knowledge in the development of better therapies for cancers. Altered 
metabolism is a key feature of not just malignancies but also a number of in-born errors 
of metabolism (IEM). Chapter 1 expounds on the common metabolic themes between 
IEM and transformed cells. Chapter 1 further introduces clear cell renal cell carcinoma 
(ccRCC) as a model for studying metabolic rewiring. I focus on the role of urea cycle 
enzymes argininosuccinate synthase 1 (ASS1), argininosuccinate lyase (ASL), and 
arginase 2 (ARG2) in ccRCC progression. The urea cycle is downregulated in ccRCC 
tumors when compared to the normal kidney, and I hypothesize that urea cycle enzymes 
act as potential metabolic tumor suppressors in ccRCC. 
In Chapter 3, I demonstrate that urea cycle enzymes and intermediates have 
lowered abundances in ccRCC tumors when compared to the normal kidney. 
Furthermore, loss of these enzymes enhances proliferation in normal kidney cells, while 
their re-expression suppresses growth in ccRCC cells.  
ARG2 is a mitochondrial enzyme that is lost in ccRCC tumors. Loss of ARG2 
promotes tumorigenesis in two important ways – preserving intracellular pools of 
pyridoxal phosphate and preventing a toxic build-up of polyamines (Figures 12-14). 
Thus, ARG2 is a key regulator of cellular growth in ccRCC tumors, and its loss alters 
arginine metabolism while promoting malignant transformation.  
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In addition to ARG2, ccRCC tumors also downregulate two additional urea cycle 
enzymes ASS1 and ASL. These enzymes are spatially distinct from ARG2, as they 
reside in the cytosol. ASS1 and ASL lie at a critical metabolic hub in the cell. Reactions 
catalyzed by these enzymes are involved in aspartate catabolism, and arginine and nitric 
oxide biosynthesis. Loss of ASS1 and ASL helps cells redirect aspartate towards 
pyrimidine synthesis (Figure 22) and support enhanced proliferation. Although the role of 
aspartate conservation and ASS1 and ASL loss have been discussed extensively 
elsewhere, my work elucidates their importance in ccRCC. Furthermore, my research 
indicates that though ASL expression alone does not suppress growth in ccRCC cells, it 
impacts tumor vasculature, perhaps through its role in nitric oxide synthesis. 
Overall, my work adds to our understanding of urea cycle enzymes in a context 
independent of ureagenesis, their role in ccRCC progression, and uncovers novel 
potential metabolic vulnerabilities in ccRCC. 
Future Directions 
Exploring non-enzymatic contributions of ASS1 and ASL in ccRCC progression 
 My work demonstrates that ARG2 mediated suppression in ccRCC depends on 
its catalytic activity (Figure 6). However, the same has not been explored for ASS1 and 
ASL. Erez et al., have determined a structural role for ASS1 and ASL in nitric oxide (NO) 
synthesis. ASS1 and ASL form a tripartite complex with nitric oxide synthase (NOS) and 
shuttle the arginine produced by ASL towards NO generation. With this background we 
have generated point mutations in ASS1 and ASL that render them catalytically inactive. 
The goal is to re-express the catalytically dead versions of these enzymes in ccRCC 
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cells and evaluate the effect on growth. Furthermore, it will be intriguing to assess the 
tripartite complex formation in kidney cells and the effect of malignant transformation in 
ccRCC (Erez et al., 2011).  
 
Investigating the role of ASS1 and ASL in Nitric Oxide Synthesis 
As the reactions catalyzed by ASS1 and ASL are also a part of the citrulline-NO 
cycle, it would be important to investigate the effect of their loss on NO synthesis. 
Jansson et al., reported lowered NOS activity in ccRCC tumors. Our preliminary studies 
validate these results (data not shown). It will be interesting to further explore the effects 
of NOS downregulation in ccRCC. NO is a potent regulator of vascular tone and ccRCC 
tumors are highly vascular. It will be critical to establish a role for lowered NO signaling 
in ccRCC tumors with VHL loss and HIF activation. (Jansson et al., 1998). 
Evaluating the role of the urea cycle in ccRCC tumor immune microenvironment  
 Urea cycle loss naturally makes ccRCC cells arginine auxotrophs (Figure 5). As 
tumor infiltrating T cells clearly rely on arginine for their cytotoxic activity (Geiger et al., 
2016), ccRCC cells’ dependency on circulating arginine suggests that this metabolic 
adaptation contributes to immunosuppression in the tumor microenvironment.  
Competition for microenvironmental arginine and serine, (Ma et al., 2017), provides an 
explanation for the success of immune checkpoint blockade in only a subset of ccRCC 
patients (Hammers, 2016; Joseph et al., 2017). If ccRCC tumor cells deprive infiltrating 
lymphocytes (and other immune cells) of critical exogenous metabolites due to urea 
cycle deficiency, overcoming the effects of PD-1/PD-L1 activity would fail to fully restore 
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anti-tumor immunity. Our findings also raise the intriguing possibility that immunotherapy 
approaches could be improved by dietary means (i.e. arginine supplementation) for 
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